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Desde los tiempos míticos, el hombre ha soñado con la posibilidad de que sus tejidos 
dañados por la enfermedad, las heridas o la senescencia pudiesen ser regenerados y 
sustituidos por unos nuevos plenos de vida 
La medicina regenerativa o Ingeniería Tisular es una de las ramas de la investigación 
biomédica que más se ha desarrollado en los últimos años y que al mismo tiempo 
presenta unas perspectivas de futuro prometedoras. 
Desde un punto de vista un tanto academicista, que permite simplificar el abordaje del 
tema, consideramos que esta estrategia terapéutica se basa en tres pilares: 
1. Lo que podríamos denominar en sentido amplio como Tisugénesis. Serían los 
aspectos ligados a las células. Una serie de células poco especializadas que 
desde los estudios de Friedenstein en el principio de los años 70 se ha dado 
en denominar Mesenchimal Stem cell o células madre mesenquimales. Estas 
células inicialmente identificadas en la médula ósea donde coexisten con las 
células progenitoras hematopoyéticas (también conocidas como 
Hematopoietic Stem cell) y que posteriormente han sido identificadas en 
muchos otros tejidos, tienen la capacidad de diferenciarse en células más 
específicas de un tejido. En realidad se trata de poblaciones celulares más o 
menos heterogéneas y que en su conjunto y mediante estímulos específicos –
ya sea mecánicos, eléctricos o bioquímicos- son capaces de responder 
modificando su fenotipo y comportándose como células específicas y 
características de un determinado tejido. Estas células deben cumplir una 
serie de criterios conforme a lo que indica la International Society for 
Cellular Therapy (ISCT).  Son células mononucleadas de aspecto 
fibroblastoide capaces de adherirse al plástico de los frascos de cultivo, con 
un perfil de marcadores de superficie que incluye (CD73+ CD90+ CD105+  
CD34-  CD45-  CD11B-  CD14-  CD19-  CD79a-  HLA-DR- ) y capaces de 
diferenciarse al menos a tres líneas celulares: óseas, condrocitos y adipocitos. 
2. Tisuconducción. Este es un aspecto ligado al desarrollo de biomateriales. 
Estructuras que por sus características mecánicas, eléctricas de superficie, 
estructura porosa o composición, permiten a las células tener un soporte 
estructural que favorezca la dirección del crecimiento celular que lo asemeje 
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a la estructura del tejido que queremos mimetizar. Estos andamiajes han sido 
desarrollado bien como derivados orgánicos o directamente sintetizados en el 
laboratorio. Y en ambos casos pueden ser estructuras poliméricas o 
minerales. Entre las estructuras poliméricas, vemos como se han desarrollado 
las derivadas de proteínas como el colágeno, de azúcares como el chitosano 
o las caprolactonas o bien derivados de los ácidos láctico y glicólico. En 
cuanto a los derivados inorgánicos, y especialmente en cuanto respecta a los 
diseños encaminados a la obtención de soporte óseo, la utilización de 
derivados de los fosfatos cálcicos dopados con distintos iones es la más 
utilizada. Así la síntesis de diversos derivados de las hidroxiapatitas con 
contenidos variables en pirofosfatos, Sr, Mg, Si, e incluso la adición de 
polisacáridos como el condroitin sulfato permiten modular la respuesta 
mecánica y biológica de estos compuestos. La tendencia más actual es la de 
construir matrices compuestas en las que la nanotecnología y las nanofibras 
tienen una importancia parece que capital. 
3. Tisuinducción. Este es el aspecto más ligado con el conocimiento de la fisiología 
de los organismos vivos. El conocimiento de los estímulos que van a poner 
en marcha los mecanismos de diferenciación celular, de modificación de su 
expresión genética y por tanto de apariencia morfofuncional. El 
conocimiento del mediador, de su receptor específico o general y la 
secuencia de actuación permite modular el proceso regenerativo. Factores 
como las proteínas morfogenéticas, hormonas y polipéptidos se han 
encontrado eficaces en estimular el cambio celular. 
 
En la memoria que hemos redactado presentamos algunos de los trabajos realizados en 
estas direcciones, y que deberían naturalmente converger para construir un complejo en 
el que se combinaran las estructuras de soporte diseñadas como matrices híbridas 
fosfocálcicas y poliméricas en las que la reabsorción estuviese modulada por los 
tiempos de sustitución de matriz neoformada por las células multipotenciales 
consideradas anteriormente. También dedicamos un esfuerzo importante en el estudio 
de los factores que determinan o ayudan en la diferenciación celular. 
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En concreto presentamos cinco artículos que hemos ordenado cronológicamente. 
El primero de ellos se refiere a la capacidad que presenta la hormona de crecimiento 
administrada en forma tópica en el lecho quirúrgico preimplantario para estimular el 
crecimiento de hueso. En un modelo experimental animal se realizó un análisis 
histomorfométrico del hueso obtenido en periimplantes colocados en tibias,  frente al 
hueso obtenido en situación similar pero administrando tópicamente 4IU de hormona de 
crecimiento recombinante humana.  Los resultados indican que se produce un aumento 
significativo del volumen óseo y del contacto del hueso con los implantes colocados.  
En la segunda publicación abordamos el aspecto del soporte. Nuevamente en un modelo 
animal que modificamos para el estudio, analizamos la formación de hueso aplicando 
un cemento derivado del fosfato cálcico sintetizado por el grupo de trabajo que se 
reabsorbe en un tiempo más acorde con la velocidad de neoformación ósea. Los 
resultados muestran como la cantidad de  hueso neoformado es significativamente 
superior con el nuevo material. 
En la tercera publicación considerada, nos centramos en el plasma rico en plaquetas 
como medio de estimular la regeneración ósea. Realizamos un estudio comparativo 
entre dos sistemas para obtener el concentrado plaquetario evaluando la concentración 
obtenida y la ultraestructura (mediante microscopía electrónica de transmisión) del 
concentrado plaquetario activado. 
Los dos siguientes trabajos analizan en un modelo animal el efecto de la aplicación del 
plasma rico en plaquetas en un defecto óseo crítico experimental. Los resultados indican 
que la aplicación del plasma rico en plaquetas aumenta la precocidad de la reparación 
tisular, que la aparición de osificaciones más precoz, pero que a medio o largo plazo no 
existe más regeneración ósea sino un mayor componente fibroso. 
Las conclusiones finales a las que llegamos con estos trabajos hacen pensar que: 
El diseño de nuevos biomateriales permite favorecer la regeneración ósea en cuanto a 
volumen. Que la aplicación de osteoinductores como la GH va a conseguir un efecto 
positivo en el volumen y calidad del hueso neoformado. Y que el plasma rico en 
plaquetas añadido a los lechos quirúrgicos en ausencia de un sustrato osteoconductor 
mejora inicialmente la regeneración, pero sin efecto significativo a medio o largo plazo. 
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
 
 
8 
 
From mythical times, man has dreamed of the possibility that their tissues damaged by 
disease, wounds or tissue senescence could be regenerated and replaced by new ones 
full of life. 
Regenerative medicine or tissue engineering is one of the biomedical research branches 
which it has developed more in recent years and that at the same time present promising 
future prospects. 
From a viewpoint somewhat academic, to simplify the approach to the issue, we believe 
that this therapeutic strategy is based on three pillars: 
1. What we might be called broadly as Tisugénesis. Would the aspects linked to the 
cells. A series of little specialized cells that Friedenstein from studies in the early 70s 
has been called Mesenchimal Stem cell or mesenchymal stem cells. These initially 
identified in the bone marrow where they coexist with hematopoietic progenitor cells 
(also known as Hematopoietic Stem cell) and have subsequently been identified in 
many other tissues, cells have the ability to differentiate into more tissue-specific cells. 
Actually it is more or less heterogeneous cell populations and that as a whole and by 
specific stimuli-whether mechanical, electrical or biochemists are able to respond by 
changing their phenotype and behaving like cells and specific characteristics of a 
particular tissue. These cells must meet certain criteria under which indicates the 
International Society for Cellular Therapy (ISCT). They are looking fibroblastoid 
mononuclear cells able to adhere to plastic culture flasks, with a profile of surface 
markers including (CD73 + CD90 + CD105 + CD34- CD45- CD14- CD19- CD11B- 
CD79a- HLA-DR) and capable of differentiate at least three cell lines: bone, 
chondrocytes and adipocytes. 
2. Tisuconducción. This is linked to the development of biomaterials appearance. By 
their structures, electrical surface porous structure or composition, mechanical 
characteristics allow cells to have a structural support that promotes cell growth 
direction close as the tissue structure we mimic. These scaffolds have been developed 
well as organic derivatives or directly synthesized in the laboratory. And in both cases 
may be mineral or polymeric structures. Among the polymeric structures, as we have 
developed derived from proteins such as collagen, sugars such as chitosan or 
caprolactones or derived from lactic and glycolic acids. As for the inorganic derivatives, 
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and in particular as regards to the designs aimed at obtaining bone support, the use of 
derivatives of calcium phosphates doped with various ions is most often used. Thus the 
synthesis of various derivatives of hydroxyapatites with variable contents in 
pyrophosphates, Sr, Mg, Si, and even the addition of polysaccharides such as 
chondroitin sulphate are used to modulate the mechanical and biological response of 
these compounds. The current trend is to build composite matrices in which 
nanotechnology and nanofibers have an importance seems that capital. 
3. Tisuinducción. This is linked with the knowledge of the physiology of living 
organisms aspect. Knowledge of stimuli that will implement the mechanisms of cell 
differentiation, modifying their genetic expression and therefore morfofuncional 
appearance. Knowledge of the mediator, its specific or general receiver and modular 
actuation sequence allows the regenerative process. Factors such as morphogenetic 
proteins, hormones and polypeptides have been found effective in stimulating cell 
turnover. 
In memory that we have written are some of the work done in these directions, and 
should naturally converge to build a complex in which the support structures designed 
as hybrid matrices phosphocalcic and polymer in which resorption were modulated by 
will combine the replacement times for the newly formed matrix multipotent cells 
considered above. We also spent a considerable effort in the study of the factors that 
determine or help in cell differentiation. 
Specifically are five items that we ordered chronologically. 
The first one relates to the ability that presents growth hormone administered topically 
in the surgical bed preimplantario to stimulate bone growth. In an animal experimental 
model analysis histomorphometric was performed of bone obtained in periimplantes 
placed in tibia´s, compared to bone obtained in a similar situation but topically 
administering 4IU of recombinant human growth hormone. The results indicate that it 
produces a significant increase in bone volume and bone contact with the implants 
placed. 
In the second publication we boarded the appearance of the support. Again in an animal 
model for the study modify, analyze bone formation by applying a derivative of calcium 
phosphate cement synthesized by the working group that is reabsorbed in a line with the 
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speed of bone formation time. The results show that the amount of new bone is 
significantly higher with the new material. 
In the third publication considered, we focus on the PRP as a means to stimulate bone 
regeneration. A comparative study between two systems for evaluating the platelet 
concentrate concentration obtained and the ultrastructure (transmission electron 
microscopy) activated platelet concentrate. 
The next two papers analyze in an animal model the effect of the application of PRP in 
a critical experimental bone defect. The results indicate that application of platelet-rich 
plasma increases precocious tissue repair, the earliest appearance of ossification, but 
that medium to long term there is no more bone regeneration but more fibrous 
component. 
Final conclusions arrived with this work suggest that: 
The design of new biomaterials can promote bone regeneration in volume. The 
application of osteoinductive as the GH is going to get a positive effect on the volume 
and quality of new bone. And the PRP added to the surgical bed in absence of an 
osteoconductive substrate improves regeneration initially, but without significant effect 
at medium or long term. 
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Resolvió Zeus vengarse de Prometeo por su engaño, y negó a los mortales el último don 
que necesitaban para alcanzar la plena civilización: el fuego. Más, también aquí supo 
componérselas el astuto hijo de Japeto. Cogiendo el largo tallo del jugoso hinojo gigante, 
se acercó con él al carro del Sol que pasaba y prendió fuego a la planta. Provisto de 
aquella antorcha bajó a la Tierra y pronto la primera hoguera flameó hacia el Cielo…. 
…Después, Zeus dirigió su venganza contra Prometeo. Entregó al culpable a Hefesto y sus 
criados, Cratos y Bia (la coerción y la violencia), quienes hubieron de arrastrarle a las 
soledades de Escitia, y allí, sobre un espantoso precipicio, encadenarle con cadenas 
indestructibles al muro de roca del Cáucaso. Hefesto cumplió con desgano el mandato de 
su padre, pues amaba en el hijo de los Titanes al consanguíneo descendiente de su abuelo 
Urano, a un vastago de los dioses de tan alta alcurnia como Zeus. Con palabras llenas de 
piedad y bajo los improperios de sus brutales servidores, mandó a estos a que efectuaran el 
cruel trabajo…. 
…Y así hubo de permanecer Prometeo suspendido de la desolada peña, de pie, insomne, 
sin nunca poder doblar la cansada rodilla. «Exhalarás muchas inútiles quejas y suspiros —
le díjo Hefesto—, pues la voluntad de Zeus es inexorable, y todos aquellos que llevan 
poco tiempo disfrutando de un poder usurpado son duros de corazón». En realidad, el 
tormento del cautivo debía durar eternamente, o por lo menos treinta mil años. Aunque 
suspirando y quejándose a voces, aunque llamando, como testigos de su dolor, a los 
vientos y a los ríos, a las fuentes y a las olas del mar, a la madre Tierra y a los astros del 
Zodíaco que todo lo ven, su. ánimo no se doblegó. «Debe soportar la decisión del Destino 
—dijo— todo aquel que sabe comprender la fuerza invencible ce la necesidad». Tampoco 
se dejó mover por las amenazas de Zeus a descifrar la oscura profecía de que un nuevo 
lazo matrimonia depararía al soberano de los dioses la perdición y la caída. Zeus cumplió 
su palabra: envió al prisionero un águila que, huésped diario, se nutría de su hígado, el 
cual, consumido, se regeneraba constantemente.1  
La idea de la pervivencia y de la inmortalidad, ha ocupado siempre un lugar preponderante 
en la mente humana. La necesidad de ir más allá de la muerte se plasma en numerosos 
mitos y leyendas. 
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En este conocido pasaje de la mitología griega, Prometeo es castigado por Zeus  y en su 
tortura aparece una referencia a lo que hoy entendemos como regeneración tisular. 
La reconstrucción de los defectos óseos maxilofaciales constituye hoy en día uno de los 
mayores retos en el campo de la odontología, destacando su importancia  en el 
tratamiento con implantes y en el área de la periodoncia. Aunque el tratamiento de la 
pérdida dentaria con implantes aloplásticos constituye en la actualidad una alternativa 
terapéutica con un excelente pronóstico, la necesidad de realizar modificaciones de los 
tejidos de soporte puede llegar a alcanzar un porcentaje elevado de los casos. Así 
Martínez2 considera que entre el 25% y el 72.3% de los casos presentan una 
reabsorción ósea subsidiaria de ser tratada mediante técnicas quirúrgicas avanzadas. En 
este sentido se han preconizado técnicas como la regeneración ósea guiada3, la 
utilización de injertos4,5,6, o la aplicación de biomateriales7,8 para conseguir un mejor 
soporte óseo. 
Bone Engineering de J.E.Davis es un texto esencial en el conocimiento sobre la 
regeneración del hueso y por extensión de los tejidos en general. En el prólogo de 
Vacanti9 refiere (hace ya 15 años) el explosivo interés que tanto profesionales como 
público han desarrollado acerca de la promesa de nuevas estrategias terapéuticas 
basadas en la ingeniería de tejidos.  
Podemos definir la ingeniería tisular como la parte de las ciencias biomédicas que 
desarrolla la regeneración de los tejidos mediante terapias basadas en el control del 
reclutamiento, la multiplicación y  la diferenciación celular, su estímulo mediante 
factores de inducción y contención asociados al diseño de estructuras tridimensionales 
que permitan el soporte de la estructura celular remedando la estructura del tejido. Es 
decir la combinación de diseño de materiales bioactivos, la aplicación de sustancias 
tisuinductoras y la selección de estirpes celulares regeneradoras. 
Los 100 trillones de células que tiene el organismo humano, se encuentran repartidos en 
unos 260 diferentes fenotipos que se asocian en el tiempo y el espacio para formar los 
tejidos y los órganos. Han seguido un proceso de diferenciación que consiste en adquirir 
un conjunto de características morfofuncionales y bioquímicas distintas al resto de los 
conjuntos celulares. Generalmente cuanto mayor es el grado de expresión de 
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características fenotípicas, menor es la capacidad de multiplicación de estas células. Sin 
embargo hay algunas células que manteniendo su capacidad de dividirse son capaces de 
expresar un morfotipo determinado bajo condiciones específicas de crecimiento. 
Friedenstein, en los años 70, identificó en la médula  ósea unas poblaciones  celulares 
no hematopoyéticas capaces de renovarse y de dar lugar a células óseas. En 1991 
Caplan utiliza el término de “células madre mesenquimales” al determinar la capacidad 
de diferenciarse también a otras líneas esqueléticas3. Fueron definidas como una 
población de células mononucleares derivadas de la médula ósea que cultivadas ex vivo 
se adherían al plástico, tenían una morfología fibroblástica, formaban colonias y eran 
capaces de diferenciarse en varias líneas celulares, en especial en hueso, cartílago y 
adipocitos. Posteriormente han sido identificadas también en muchos otros tejidos como 
músculo, tejido adiposo, pulpa dental, periodonto, etc. 
En la actualidad la ISCT (International Society for Cellular Therapy)  ha incluido como 
requisito, un patrón de expresión de marcadores antigénicos que responde a ( CD73+ , 
CD90+, CD105+, y CD34-, CD45-, CD11b-, CD14-, CD19-, CD79a-, HLA-DR-)11 
Otra característica que las hace muy interesantes para su aplicación en investigación es 
su estabilidad genética. Por lo que a pesar de tener una gran capacidad de multiplicación 
son muy resistentes a la transformación. Sin embargo a medida que van envejeciendo, 
disminuye su capacidad diferenciadora. 
El siguiente aspecto que debemos considerar, al menos desde un punto de vista un tanto 
académico y que simplifica la realidad biológica separando procesos que suceden de 
forma conjunta pero que para su mejor comprensión analizamos separadamente, es la 
influencia de distintos factores solubles sobre el comportamiento de estas células.  
Según Scheller 12 El uso de señales solubles para la modulación de la formación ósea se 
ha convertido en un importante área de investigación en los últimos años. La primera 
caracterización de una BMP (bone morphogenetic protein)  se realizó en 1965. Aunque 
su aplicación para mejorar el soporte óseo en implantología no se produce hasta 28 años 
más tarde en 1993. Diversos autores 13-14 han utilizado con éxito la BMP-2 
recombinante humana para inducir la formación de hueso en modelos experimentales 
animales o clínicos. 
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Sin embargo hay otros muchos factores que pueden regular la osteogénesis como la 
hormona de crecimiento (GH)Prieto15 . Se trata de un polipéptido de 191 aminoácidos 
secretado por las células acidófilas de la adenohipófisis y actúa a través de un 
intermediario, la IGF-I que se sintetiza en el hígado pero también en otros lugares como 
tejido condral y periostio bajo el propio estímulo de la GH. Actúa estimulando la 
proliferación y diferenciación osteoblásticas directa e indirectamente, según 
Kassem16,17, a través de la citada IGF-I. En estudios experimentales en ratas viejas 
Bak18 y Andreassen19 encontraron que la GH estimula la formación de cortical ósea 
incrementando la mineralización desde el  periostio y aumentando las propiedades 
mecánicas 
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Effects of Local Administration of Growth 
Hormone in Peri-implant Bone: An Experimental
Study with Implants in Rabbit Tibiae
Isabel F. Tresguerres, MD, PhD, DDS1/Luis Blanco, MD, PhD, DDS2/Celia Clemente, MD, PhD3/
Jesús A. F. Tresguerres, MD, PhD4
Purpose: The objective of this study was to evaluate the qualitative and quantitative differences that
could appear in newly formed peri-implant bone around Screw-Vent implants placed in rabbit tibiae
when treated with local administration of growth hormone (GH). Materials and Methods: Eight New
Zealand rabbits were randomly divided into 2 groups: the experimental group, which received 4 IU of
GH in the form of lyophilized powder added to the ostectomy site before implant placement, and the
control group, which did not receive GH before implant placement. Animals were sacrificed 2 weeks
later, and histologic sections were obtained for histomorphometry and observation under light
microscopy. Results: The sections in the GH-treated group presented enhanced growth of new trabec-
ulae from the periosteal tissue, and the bone-to-implant contact in the experimental group was signifi-
cantly greater (P  .05). Discussion: Local administration of GH stimulated a more dramatic effect
than that seen previously with systemic GH administration, prompting growth from both the perios-
teum and endosteum. Conclusions: Local administration of GH at the time of implant placement could
enhance peri-implant bone reaction. INT J ORAL MAXILLOFAC IMPLANTS 2003;18:807–811
Key words: animal studies, bone remodeling, dental implants, growth hormone
Growth hormone (GH) is a peptide with 191amino acids, secreted by the anterior pituitary
gland, that stimulates the growth process, acting as a
metabolic and mitogenic regulator. Its effects are
mediated primarily by insulin-like growth factor I
(IGF-I), a peptide of 70 amino acids that is synthe-
sized in almost all tissues, but fundamentally in the
liver and in chondral tissue1 under GH stimulation.2
GH is one of the substances that regulate bone
growth and bone remodeling in vivo,3 but it has only
recently been accepted that GH may also act as a
locally produced growth factor that can be secreted
by various types of cells4 and may exert both
endocrine as well as paracrine and autocrine effects.
GH is able to stimulate bone growth by direct
stimulation of the epiphyseal chondrocytes5 and
osteoblasts.6 GH also increases synthesis of IGF-I
and IGF-II,7 which stimulates the proliferation and
differentiation of osteoblasts.8 In addition, GH is
able to stimulate bone protein synthesis and miner-
alization9 and increase bone turnover.10
Systemic GH has been used for stimulating exper-
imental bone fracture repair in both young and old
rats, showing an increase of up to 400% in biome-
chanical properties when compared with an
untreated control group.11–14 Recent studies have
shown that GH can also have a local effect. Guicheux
and coworkers15 observed that local administration of
GH, released from a calcium phosphate–type bioma-
terial carrier, was able to improve the substitution
process of biomaterials by bone through an accelera-
tion of the bone remodeling process. 
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4Professor, Department of Physiology, Medical School, Com-
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plutense University, Plaza Ramón y Cajal s/n, Madrid, Spain. 
E-mail: f3f@eresmas.com
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However, GH has rarely been applied locally
during surgery to modify the osseointegration
process.16 The authors’ working hypothesis has
been that local administration of GH as a single
dose at the time of implant surgery could accelerate
the osseointegration process, inducing histologic
differences compared to untreated control samples.
The objectives of the present study were the
following:
1. To assess whether histologic differences appear
in the peri-implant bone with the local adminis-
tration of GH during surgery. 
2. To evaluate quantitatively the peri-implant bone
response with a morphometric analysis.
MATERIALS AND METHODS
A total of eight 3-month-old New Zealand rabbits,
weighing 2.5 kg each, were used as experimental
animals. Rabbits were randomly divided into 2
groups. Rabbits in both the control and experimen-
tal groups had one 3.38-mm Screw-Vent implant
(Paragon Implant Company, Encino, CA) placed in
the internal side of each tibia. In addition, the
experimental animals received 4 IU of recombinant
human GH (Saizen; Serono Laboratories, Madrid,
Spain) in the form of lyophilized powder placed in
the ostectomy site before placement of the implant.
After intramuscular anesthesia with ketamine
(Imalgene 1000, 0.75 mg/kg; Merial, Lyon, France)
and xylazine (Rompun, 0.25 mg/kg; Bayer, Lev-
erkusen, Germany), an incision was made on the
internal side of the tibia, at the union of the diaph-
ysis/proximal metaphysis. After detachment of the
cutaneous-periosteal tissues, the bone bed was pre-
pared for implant treatment following instructions
of the implant manufacturer, using internal/external
cooling Paragon drills. The implants were placed
and achieved primary stability; then, the periosteal
flap was sutured with Dexon sutures (Davis & Geck,
Wayne, NJ) and the skin with silk sutures. Oxyte-
tracycline was administered orally to prevent post-
surgical infection in both groups. 
The animals were sacrificed 2 weeks after
surgery. Both tibiae were dissected from their soft
tissues, fixed in 10% buffered pH 7 formaldehyde,
and embedded in 2-hydroxyethylmethacrylate resin,
according to the Donath and Breuner method,17 so
as to cut undecalcified bone and titanium simulta-
neously with the Exakt microtome (Exakt Apparate-
bau, Norderstedt, Germany). The histologic analy-
sis was conducted under a light microscope (Leica,
Wetzlar, Germany) with sections stained with Mas-
son stain and picrosirius.18 These procedures were
performed in the Department of Morphological
Sciences and Surgery at the Medical School in the
University of Alcalá de Henares, Madrid, Spain. 
A morphometric study to quantify the newly
formed bone around the implants was performed
later with a MIP-4 imaging analyzer (a computer-
ized system that performs area and volume mea-
surements; Digital Image System, Barcelona,
Spain). The parameter calculated was bone-to-
implant contact (BIC), which is defined as the
length of bone surface border in direct contact with
the implant perimeter (100%).19 The BIC was
measured at the cortical zone in contact with the
implant (cortical level) and at the medullary zone in
contact with the implant (medullary level) (Fig 1).
These measurements were made with a 10 objec-
tive in all fields of each specimen by counting the
number of intersections over the implant surface.
Finally, the results were expressed as a percentage of
the implant surface covered by bone at the cortical
and medullary levels. For each sample, various sec-
tions were obtained and one of them was randomly
used for the statistical evaluation. 
The BIC mean values ± standard error of the
mean (SEM) of each group were calculated. The
groups were tested by the Student t test. The results
and the statistical analysis were elaborated with the
SPSS 11.0 computer system (SPSS, Chicago, IL).
RESULTS
At 2 weeks after implant placement and GH treat-
ment, the experimental group sections demon-
strated a greater periosteal and endosteal response
than the control group sections. More newly
formed trabeculae could be seen in the sections with
GH. These trabeculae were thicker and more irreg-
ular than the control group sections (Figs 2 and 3).
Fig 1 BIC contact at the cortical and medullary levels.
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Birefringent neoformed collagen fibers were seen
with the picrosirius stain, when polarized. More bire-
fringent collagen fibers were seen in the sections with
GH than in the sections without GH (Figs 4a and 4b).
The quantitative morphometric analysis obtained
with the MIP-4 analyzer showed more BIC in the
GH group, with statistical significance (Table 1;
Figs 5 and 6). Mean BIC ± SEM at the cortical level
was 66.67% ± 4.9% in the experimental group and
28.78% ± 2.6% in the control group, which was sta-
tistically significant (P  .05). Mean BIC ± SEM at
the medullary level was 51.49% ± 6.9% in the GH
group and 18.34% ± 2.5% in the control group,
which was also statistically significant (P  .05).
DISCUSSION
In recent years, several substances have been used to
improve peri-implant bone response: bone morpho-
genetic proteins,20,21 growth factors,22 and more
recently hormones, such as GH.16,23 Systemic admin-
istration of GH has been used to increase bone mass14
and to improve the fracture repair processes.11,12
Other authors have studied the stimulating effects of
local GH on bone formation in rat mandibles24 or the
enhancing effects of local GH on formation of new
bone and bone resorption using a phosphate/calcite
matrix GH-releasing system.15 The authors’ previous
data have also shown an increase in the peri-implant
bone response with the local administration of GH in
an osteoporotic rabbit model.16
The present histologic results showed an increase
in newly formed bone trabeculae in the GH-treated
group, derived from the periosteum and eventually
from the endosteum. These findings are partially in
disagreement with the results of most authors con-
ducting research in this area, who propose that GH
can stimulate the periosteal reaction without affecting
the endosteum. Andreassen and coworkers,14,25
Fig 2 Section obtained from a specimen without GH, showing
poor periosteal and endosteal response (Masson; original magni-
fication 10).
Fig 3a Section from a specimen with GH showing a greater
periosteal and endosteal response. In this case the new trabecu-
lae were mostly mineralized (green) and were perpendicular to
the old cortex (Masson; original magnification 10).
Fig 3b Section from another specimen with GH, with more
endosteal and periosteal reaction than the section shown in Fig
3a. In this specimen, the new trabeculae were more disorganized
and more irregular, and less mineralization had occurred than in
the previous specimen (Fig 3a) (Masson; original magnification
10).
Fig 3c Section from another specimen with GH, with an exag-
gerated reaction from the endosteum and fundamentally from
the periosteum. The new periosteal trabeculae can be seen;
some of them are perpendicular and mineralized. In another
area, the new periosteal trabeculae were irregular, without zones
of mineralization (Masson; original magnification 10).
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Mosekilde and associates,26 and Martínez and col-
leagues27 showed that systemic GH was able to
increase the cortical mass exclusively from the perios-
teum. In the present results, the endosteal reaction
could have been induced by the high local levels of
GH. The newly formed trabeculae were more irregu-
lar in the GH group. However, Jorgensen and
coworkers28 observed newly formed bone after the
systemic administration of GH in growing rats and
concluded that it had the characteristics of normal
bone, with concentric lamellae forming osteons. The
present results suggest that locally administered GH
in a single dose of 4 IU (1.2 mg) could exert an
“impulse effect” in the first hours of the process of
osseointegration,16 recruiting more preosteoblasts
and thus leading to an acceleration of the process. 
The morphometric data revealed that there was
significantly greater BIC in the GH-treated group
than in the control group. These results obtained
with the local application of GH are similar to those
of Lynch and associates,22 who observed that local
administration of platelet-derived growth factor and
IGF-I were capable of stimulating the regeneration
of bone around titanium dental implants in the early
phases of healing. These data are in agreement with
Cochran and colleagues,20 who found more BIC in
implants that were treated with local recombinant
human bone morphogenetic protein-2.
CONCLUSION
The local administration of GH was able to
enhance the peri-implant bone response around
Screw-Vent implants placed in young rabbit tibiae
at a statistically significant level.
Fig 4a Section from a specimen without GH seen under polar-
ized light, showing lesser birefringent neoformed collagen fibers
(picrosirius; original magnification 10).
Fig 4b Section from a specimen with GH seen under polarized
light, showing more birefringent neoformed collagen fibers
(picrosirius; original magnification 10).
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Fig 5 Cortical bone-to-implant contact. In the experimental
group, mean BIC (± SEM) was 66.67% ± 4.9%, and in the control
group, mean BIC was 28.78% ± 2.6%. These differences were
statistically significant (P .05).
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Fig 6 Medullary bone-to-implant contact. In the experimental
group, mean BIC (± SEM) was 51.49% ± 6.9%, and in the control
group, mean BIC was 18.34% ± 2.5%. These differences were
statistically significant (P .05).
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Table 1 Bone-Implant Contact in Examined
Species
Implant Cortical Medullary
sample BIC (%) BIC (%)
Control group (no GH)
1 18.11 16.03
2 33.94 29.22
3 35.96 16.21
4 26.82 18.06
5 27.71 22.68
6 38.03 10.72
7 31.70 25.88
8 18.00 7.98
Experimental group (with GH)
1 52.48 47.91
2 43.03 35.32
3 64.31 43.11
4 65.09 35.31
5 66.02 28.62
6 80.75 68.61
7 77.31 71.37
8 84.44 81.67
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Bone augmentation in rabbit
calvariae: comparative study
between Bio-Osss and a novel
b-TCP/DCPD granulate
Tamimi FM, Torres J, Tresguerres I, Clemente C, Lo´pez-Cabarcos E, Blanco LJ. Bone
augmentation in rabbit calvariae: comparative study between Bio-Osss and a novel
b-TCP/DCPD granulate. J clin Periodiontol 2006; 33: 922–928. doi 10.111/j.1600-
051X.2006.01004.x.
Abstract
Aim: In the present in vivo study, we compare the bone regeneration capacity of a
novel brushite cement synthesized in our laboratory (DTG) with Bio-Osss using
rabbits as an animal model.
Methods: The study was performed in a group of 14 adult New Zealand rabbits using
the bone conduction model. Two titanium cylinders were fixed into perforated slits
made on the parietal cortical bone of each rabbit. One cylinder was left empty
(negative control) and the other was filled with either Bio-Osss or brushite set-cement
granules (test cylinder). Four weeks after the intervention, the animals were sacrificed
and biopsies were taken. The following parameters were analysed: bone tissue
augmentation, bone mineral density and biomaterial resorption. The comparison of
data between the different groups was performed using the Mann–Whitney test with a
significance level of po0.05.
Results: The mean bone mineral density and augmented mineral tissue inside the test
cylinders were similar but higher than those of negative controls. Material resorption
and bone tissue augmentation were significantly higher in the defects treated with the
brushite-based set cement (po0.05).
Conclusions: Brushite cement granules were more resorbable and generated more
bone tissue than Bio-Osss inside the titanium cylinders placed in the rabbit calvaria.
Key words: Bio-Osss; Brushite; b-tricalcium
phosphate; glycolic acid; titanium bone
cylinder; vertical bone augmentation
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Bone regeneration techniques constitute
a valid surgical procedure for increasing
bone quantity and quality in areas where
insufficient bone volume prevents
the stabilization of osteointegrated
implants. Biomaterials for stimulating
osseous regeneration should combine
osteogenic, osteoinductive and osteo-
conductive properties. Besides, they
should be resorbed and gradually
replaced by newly formed bone
(Giannoudis et al. 2005). The use of
several bone substitutes has been
described for bone regeneration but so
far, only autografts (autologous bone
grafts) re-unite all the mentioned prop-
erties, being the most suitable material.
However, the limited availability of auto-
grafts in intra-oral areas and the post-
operative morbidity associated with the
use of extra-oral grafts forces the physi-
cians to use other biomaterials in bone
regeneration (Block & Kent 1997).
An alternative to autografts are allo-
genic biomaterials (grafts from another
individual of the same species), such as
human demineralized freeze-dried bone,
provided by tissue banks. Unfortunately,
there is some controversy regarding the
osteoinductive capability of these materi-
als (Schwartz et al. 1998); besides, they
have the risk of immunological rejection
and transmission of infections such as
HIV and hepatitis that requires special
manufacture measurements (Giannoudis
et al. 2005). Currently, only bone mor-
phogenetic proteins (BMP) seem to have
osteoinductive properties but their use for
dental practice is still in the experimental
phase (Nevins 1996).
The osteoconductive properties offered
by natural bone substitutes from animal
origin, such as collagens and bovine
hydroxyapatite Bio-Osss (Geistlich Bio-
materials, Wolhusen, Switzerland) over-
come some of the autografts’ limitations
(Von Arx et al. 2001). For instance,
Bio-Osss chemical composition is very
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similar to that of human bone hydroxya-
patite (HA) as it contains a calcium/
phosphate proportion of 1.67 identical to
bone HA (Suzuki et al. 2000). Besides, its
mineral matrix contains crystals of ca.
100mm diameter, presenting morphologi-
cal and structural properties very similar
to those of the human bone (Rosen et al.
2002). Furthermore, Bio-Osss rough
topography favours osteoblastic ancho-
rage, proliferation and synthesis of bone
matrix on its surface (Acil et al. 2000),
and is currently one of the most fre-
quently used biomaterials in bone regen-
erative procedures. However, HA-based
biomaterials are very slowly resorbed
in vivo.
Third-generation biomaterials are
designed with the aim to aid the body
in self-healing. One desirable character-
istic in bone materials is their ability to
be remodelled, i.e. the biomaterial is
resorbed by osteoclasts and subsequently
replaced by newly formed bone through
osteoblastic activity (Schilling et al.
2004). Biomaterials with a slow resorp-
tion rate, such as HA, interfere with bone
growth, while biomaterials with a fast
resorption rate, such as calcium sul-
phates, compromise the stability of the
surgical site during the healing process
(Stavropoulos et al. 2004, Lieberman
et al. 2005). New biomaterials are designed
to have resorption speeds that match bone
growth rate. It is to be noted that brushite
crystals have an in vivo resorption rate
similar to human bone growth speed, ca.
20mm/day, and this fact can be very
important in stabilizing the newly formed
bone. (Bohner et al. 2005).
Synthetic materials, such as b-trical-
cium phosphate (b-TCP) and dicalcium
phosphate dehydrate (brushite or DCPD)
raise great interest as they are cheap, do
not present immunologic or infectious
problems (Giannoudis et al. 2005) and
have a higher resorption rate in vivo than
HA materials, allowing bone formation
simultaneously with material resorption
(Chow et al. 2003, Trisi et al. 2003).
In 1987, Mirtchi and Lemaitre intro-
duced the first cement made from DCDP
and b-TCP obtained from the reaction of
a base (b-TCP) and an acid (mono-
calcium phosphate). The set cement
composition presented a mixture of
two minerals: b-TCP and DCDP
(Mirtchi & Lemaitre 1989). The signifi-
cance of this cement lies in its capacity
to decompose in physiological environ-
ments and be resorbed by the body.
Investigations performed on this cement
showed that DCDP is resorbed up to
three times faster than HA or b-TCP
(Chow et al. 2003). This property seems
to prove its feasibility in accelerating
the substitution of the biomaterial by
newly formed bone. Surprisingly, this
biomaterial has barely been studied for
dental implantology purposes, although
it has proved to be useful in orthopaedic
applications for stabilizing fractures or
filling defects (Bohner et al. 2005).
Most investigations that evaluate the
bone-forming capacity of biomaterials
are performed in critical size defect
(CSD) models (see Fig. 1a). However,
in daily clinical practice, bone regenera-
tion is often needed to grow vertically
from the surface of the native bone, i.e.
a vertical bone augmentation. The eva-
luation of bone-regeneration is better
performed with the bone conduction
model (Fig. 1b), introducing barriers in
the bone defect that prevent lateral bone
formation and allow bone growth only
in the vertical direction (Lundgren et al.
1999, 2000).
The purpose of this study was to
evaluate the bone-regenerative capacity
of a novel brushite/b-TCP pre-set cement
in granular form (DTG) and to compare
its behaviour with the commercial bovine
bone Bio-Osss. The two biomaterials
were implanted in rabbits using a
calvaria, a titanium cylinder bone con-
duction model, and new bone tissue
formation was analysed 4 weeks after
the intervention.
Material and Methods
Before beginning the ‘‘in vivo’’ animal
study, the protocol was approved by the
ethical committee for animal experi-
ments of the Complutense University
of Madrid (UCM). Experiments were
conducted in accordance with the
guidelines laid down by the European
Communities Council Directive of 24
November 1986 (86/609/EEC), and
adequate measurements were taken to
minimize pain and discomfort in the
animals.
The preparation of the new biomater-
ial is explained elsewhere (Tamimi et al.
2005) but herein a brief description of
the synthesis is given (Tamimi et al.
2005). The new biomaterial (DTG) was
made from a brushite cement composed
of monocalcium phosphate (0.8 g) and
b-TCP (1.4 g) that sets in a glycolic acid
aqueous solution (1M) using a powder
to liquid ratio of 1.7 g/l. The cement was
left to set ex vivo into a hard material
that was milled with a mortar and sieved
to obtain granules with diameter ranging
between 0.2 and 1.0mm. The final com-
position of the granules was 87% DCPD
and 17% b-TCP (Tamimi et al. 2005).
Bovine bone regeneration biomaterial
Bio-Osss was acquired from Geistlich
Biomaterials (Baden, Germany). The in
vivo study was performed in a rabbit
experimental model using a titanium
bone conduction cylinder. The titanium
cylinders (Apositos Sanitarios Aragon-
eses, Huesca, Spain) had an inner rough
surface with the following dimensions:
4mm height, 0.5mm thickness and 9mm
inner diameter.
Fourteen healthy 6-month-old female
New Zealand rabbits weighing between
3.9 and 4.4 kg were used as experimen-
tal animals in order to compare in vivo
the bone augmentation capacity of
Bio-Osss with DTG (Tamimi et al.
2005). The animals were accommodated
in the official stable for animal assays of
the UCM at 22–241C with 55–70%
humidity, light cycles of 12 h, and air
renewal 15 times/h. The rabbits were
fed with a Panlabs (Panlab S.L., Barce-
lona, Spain) diet while drinking was
permitted ad libitum. The rabbits were
divided into two groups of seven each,
the first group was to be treated with
Bio-Osss (group 1) and the second
group with DTG (group 2).
Surgical procedure
The rabbits were anaesthetized with
an intra-muscular dose of 0.75mg/kg
ketamine (Imalgene 1000s, Rhone,
Merieux, France) and 0.25mg/kg xila-
cine (Rompuns, Bayer, Leverkusen,
Germany). Animals were placed in ster-
nal recumbency, the head was shaved
and the cutaneous surface was disin-
fected with a povidone iod solution
before the operation. The calvaria bone
was exposed through a skin incision
Fig. 1. Schematic representation of two pos-
sible methods for evaluating bone regenera-
tion in vivo: (a) critical-size defect model in
which bone regeneration occurs with unde-
fined direction; and (b) bone-conduction
chamber model for evaluating true vertical
bone augmentation. Bone tissue is repre-
sented as the grey background, the directions
of growth by the white arrows and the
obstacles used for limiting bone growth are
shown by the black stripes.
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approximately 4 cm in length over the
linea media. A pair of tweezers was
used to lift the skin before the perios-
tium was also incised in the same place.
A periosteal elevator was used for separ-
ating the periosteum from the bone
surface. Two circular slits (0.5mm
thick  9mm inner diameter  0.5mm
deep) were made in the parietal bone
using a trephine on a slow-speed electric
handpiece by applying 0.9% physiolo-
gic saline irrigation. The slits were made
on each side of the median sagittal
suture without crossing it. A titanium
cylinder barrier was created by mecha-
nically fixing the titanium cylinder on
each slit applying slight pressure on it.
The bone surface surrounded by the ring
was slightly roughened with a rounded
burr to promote bleeding (see Fig. 2).
The tested biomaterials are stabilized
inside the cylinders, and on each rabbit
the right cylinder was grafted with
0.25 g of experimental biomaterial
(Group 1: Bio-Osss and group 2:
DTG), while the contra-lateral chamber
was filled with autologous blood clot as
negative control (group 1: control 1 and
group 2: control 2). Closure of perios-
teum and subcutaneous tissues was per-
formed with resorbable Dexons 3/0
sutures (North Haven, CT, USA), while
the skin was relocated with (3/0) silk
continuous sutures (Apositos Sanitarios
Aragoneses, Huesca, Spain). Post-
operative antibiotics were administered,
Terramicinas (Pfizer, Madrid, Spain),
in water for 7 days. The animals
were sacrificed 4 weeks after the inter-
vention with an overdose of sodium
pentobarbital IV (Dolethals; Vetoqui-
nol, Lure, France).
Post-mortem, a surgical burr attached
to a slow-speed electrical handpiece was
used to harvest the bone blocks contain-
ing the titanium conduction cylinders
from the animal’s calvariae. Samples
were then preserved fixed in formalde-
hyde 10% buffer solution at pH 7.0
before further analysis.
Densitometry
Post-mortem bone mineral density ana-
lyses were performed on the calvaria
blocks using the XR-26 Norlands Den-
sitometer (Norland Corp.; Fort Atkinson,
WI, USA). In each calvaria block, a
bone area of 0.5  0.5 cm2 was analysed
inside both the experimental (Bio-Oss
and DTG) and control (control 1 and
control 2) chambers. The exploring reso-
lution was 1.0  1.0mm2, measuring
resolution at 0.5  0.5mm2 and explora-
tion speed at 40mm/s. The bone mineral
content (BMC) values for the experimen-
tal and control samples were obtained
from the densitometry analysis and the
bone mineral density (BMD) was calcu-
lated using the formula:
BMD ¼ BMC
Area
where the area is always 0.25 cm2, BMC
values are expressed in grams and BMD
values in g/cm2.
Histology and histomorphometry
Bone samples were dehydrated in
ascending series of alcohol (60–100%),
embedded in 2-hidroxy-ethyl-methacry-
late, and then photopolymerized 6 h with
UV light, 2 h with white light and 6 h
with blue light into ready-to-cut sample
blocks. A saw microtome Exakts
(Exact GmBH, Norderstedt, Germany)
was used to cut coronal sections from
the cylinders as described elsewhere
(Donath & Breuner 1982, Slotte et al.
2003) 200mm thick. The sections were
then ground to a total thickness of 50–
80mm by means of a grinder Exakts
(Norderstedt) in order to achieve better
histological visualization without risking
the loss of the samples. Afterwards, sur-
face staining was performed with hae-
matoxylin & eosin (HE) and toluidine
blue (TB; Donath & Breuner 1982). The
histological evaluation of bone neofor-
mation was carried out by means of
optical microscopy. To perform the his-
tomorphometric analysis, light micro-
graphs (at magnification  6) of the
biopsy slices were captured with a digital
camera and analysed with the histomor-
phometry software MIP-4 (Digital Image
System, Barcelona, Spain). Six randomly
selected slices were analysed for each
biopsy. In each section, the area inside
the cylinder was included for histomor-
phometric evaluation while the original
cortical bone and the area outside the
cylinder were excluded. The already
existing bone was lamellar while the
regenerated bone was woven and grew
inside the cylinder so both types of bone
could be easily differentiated in the his-
tological observations.
The following measurements were
taken from each cylinder: total sample
volume, newly formed bone and
remaining graft volume. These data
permit to calculate the following para-
meters: average augmented bone
volume formed in the cylinder (BV),
volume of the remaining graft material
(RG) and augmented mineralized tissue
(AMT).
BVð%Þ ¼ Newly formed bone volume
total sample volume
 100
RGð%Þ ¼ Remaining graft volume
total sample volume
 100
AMT ¼ BVþ RG
Statistical analysis
A statistical software package (SPSS 7.0,
Chicago, IL, USA) was used to analyse
the histomorphometric and densitometry
measurements by the Mann–Whitney
test. Significance for the analysis was
set at po0.05.
Results
There were no surgical complications
during the preparation of the bone
conduction cylinder and its filling with
the experimental biomaterials. After
the intervention, the animals recovered
without post-operative signs of infection
and no animals were lost during the
study.
Densitometry
As shown in Table 1, the chambers
grafted with Bio-Osss and with DTG
Fig. 2. (a): Photograph of rabbit calvaria with two slits for fixing the titanium cylinders. (b):
photograph showing the fixation of the titanium cylinders on the slits. (c): photograph
showing the right chamber grafted with Bio-Osss while the left one was kept un-grafted for
negative control.
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had similar BMD values, which are
significantly higher than those of the
ungrafted negative controls (controls 1
and 2).
Histology
The observation of the histological sec-
tions taken from the different groups of
bone conduction cylinders showed no
inflammatory reaction. In the ungrafted
chambers (controls 1 and 2) scarce bone
formation activity was observed and
only a few short and isolated trabeculae
could be distinguished on the external
surface of the cortical (Fig. 3). Neither
osteoblasts nor osteoclasts were found
in both control chambers.
In the chambers grafted with Bio-
Osss (Figs 4 and 5), implanted granules
were observed distributed over the
whole specimen area. Bio-Osss was
dyed red by HE and greyish with TB.
Bio-Osss particles presented lacunae
free from osteocytes due to their animal
origin; nevertheless, their artificial
shape differentiate them from the bone
trabecula growing around them. Bio-
Osss granules were mostly surrounded
by a thin layer of fibrous tissue at the
medium and upper tiers, and by bone
trabeculae at the lower tier (correspond-
ing to the area in contact with the
calvaria). Bone regeneration was
observed from the external surface of
the cortical to approximately 1/3 of the
height of the cylinder. However, signs
of biomaterial resorption such as pha-
gocytic cells forming Howship’s lacu-
nae on its surface, etching, pits or
resorptive trail formation could not be
identified on Bio-Osss granules. From
this observation, we infer that 4-weeks
after implantation in rabbits’ calvariae,
Bio-Osss showed osteoconductive
properties but resorption did not take
place.
In the cylinders grafted with DTG
(Figs 6–9), the remaining granules were
observed over the whole specimen area.
DTG granules were intensely dark brown
dyed by HE, while in TB the granules
had a light grey colour. DTG particles
presented a rounded morphology invaded
by neoformed bone trabeculae growing
from the external surface of the parietal
bone, especially at the lower and medium
tiers of the cylinder, and no inflammatory
foreign body reaction was observed.
Moreover, the surface of the biomaterial
showed signs of resorption such as multi-
nuclear/mononuclear phagocytic cells
forming Howship’s lacunae, surface pit-
ting, resorption trail formation, and the
remaining granules being perforated by
the new bone (see Fig. 6). This material
Table 1. BMD values of each group
Group BMD (g/cm2)
Bio-Osss 0.32  0.05n
Control 1 0.15  0.02
DTG 0.29  0.07n
Control 2 0.14  0.01
All data presented are mean values
( standard deviation).
nSignificantly higher than all control groups
(po0.05).
BMD; Bone mineral density values.
Fig. 3. Light microscope photograph of an haematoxylin & eosin-stained section from rabbit
calvaria with titanium cylinders fixed on it (black strips). (a): unfilled cylinder (negative
control), (b): cylinders grafted with Bio-Osss granules. (c): cylinder grafted with DTG
granules. The photograph shows newly formed bone growing into the Bio-Osss and DTG
granules, while no bone grows into the unfilled cylinder (original magnification  2).
Fig. 4. Light microscope photograph of a
toluidine blue-stained section from a bone
conduction chamber grafted with Bio-Osss.
The photograph shows newly formed bone
growing on the surfaces of Bio-Osss gran-
ules (original magnification  10).
Fig. 5. Light microscope photograph of a
toluidine blue-stained section from a bone
conduction chamber grafted with Bio-Osss.
The photograph shows bone forming over
the Bio-Osss surface but no resorption
pitting is observed on the granules, and their
edges remain sharp (original magnification
 20).
Fig. 6. Light microscope photograph of an
haematoxylin & eosin-stained section from
rabbit calvaria grafted with DTG. The micro-
graph shows a DTG granule (black) sur-
rounded and perforated by the newly formed
bone (red) (original magnification  20).
Fig. 7. Light microscope photograph of an
haematoxylin & eosin-stained section from
rabbit calvaria grafted with DTG. The
biomaterial (1) is surrounded by bone
tissue (n). Pitting resorption trail formation
(arrow), Hawshipapos;s lacunae and round-
ing of the surface can be observed while the
newly formed woven bone grows into the
resorbing structure of the graft (original
magnification  20).
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can be considered osteoconductive and
bioresorblable.
Histomorphometry
The data obtained from histomorphome-
try analysis are shown in Table 2. The
BV values are significantly higher for
DTG-grafted cylinders, followed by
Bio-Osss cylinders and the negative
controls. The RG values revealed that
the chambers filled with Bio-Osss pre-
sented less graft resorption than those
filled with DTG. AMT values were
similar for both Bio-Osss and DTG
cylinders, while negative controls had
lower AMT.
Discussion
Several authors consider that a 4-week
period of implantation is enough time to
observe angiogenesis and bone forma-
tion in several animal models, including
rabbits, where experimental biomater-
ials are grafted into bone defects
(Schmid et al. 1997, Boo et al. 2002,
Herron et al. 2003). In our experiment,
the histological changes that occurred in
the grafted areas during the 4-weeks of
implantation were pronounced and
allow to evaluate the differences in
bone regeneration capacity of both
assayed biomaterials.
BMD values of the Bio-Osss and
DTG grafted cylinders were similar but
significantly higher than the BMD
values of the negative controls. Even
though the densitometry analysis could
be biased by the remaining unresorbed
granules, the histomorphometric study
revealed that in the control groups, no
regenerated bone is formed. By contrast,
both the Bio-Osss and DTG groups
offered significantly higher neoformed
bone percentages.
In this study, there was no need to
use histological apposition markers for
identifying the newly formed bone
because with the titanium cylinder
model, the edges of the bone defect
were clearly limited by the walls of
the titanium cylinder (Slotte et al.
2003). On the other hand, the critical
size defect model presents problems in
identifying the original edges of the
defects and apposition markers, such as
tetracycline, are needed for recognizing
the newly formed bone (Pautke et al.
2005).
The BV values obtained in samples
treated with Bio-Osss were comparable
with that found in the literature (Slotte
& Lundgren 1999) where Bio-Osss was
grafted into silicone cylinders on rats’
calvariae (18.1%) or in titanium cylin-
ders on rabbitsapos; calvariae (19.9%;
Slotte et al. 2003). Nevertheless, the BV
value obtained with the DTG granules
was significantly higher than that
achieved with Bio-Osss. As the use of
Bio-Osss is widely spread in oral sur-
gery, the result obtained with the DTG
granules seems promising and worth
continuous investigation (Tamimi et al.
2005).
Bio-Osss is considered a non-resorb-
able material because it needs several
years (3–6 years) of implantation before
showing some slow in vivo resorption
through osteoclast activity (Taylor et al.
2002). The presence of unresorbed gran-
ules within the newly formed bone is
undesirable because it interferes with
new bone growth and compromises the
properties of the resulting tissue, affect-
ing its osteointegration capacity for
dental implants (Duda &Pajak 2004,
Stavropoulos et al. 2004, De Boever &
De Boever 2005, Zaffe et al. 2005).
Other authors claim that biomaterials
with slow in vivo resorption can inter-
fere bone growth instead of enhancing
it; however, we could not observe
this effect in our study because the
ungrafted negative control samples
always had much less bone augmenta-
tion than the samples grafted with the
experimental biomaterial (Stavropoulos
et al. 2004).
In our study, Bio-Osss showed no
signs of graft resorption, and the bioma-
terial still occupied the whole area of the
cylinder 4 weeks after the intervention.
On the other hand, DTG-implanted
granules were heavily penetrated by
the newly formed bone through pitting
and resorption trails confirming its bior-
esorption properties. This observation
was supported by the RG values, which
were significantly lower for the DTG
grafted granules.
Fig. 8. Light microscope photograph of a
toluidine blue-stained section from a bone
conduction chamber grafted with the novel
biomaterial (DTG). The photograph shows
newly formed bone (n) in direct contact with
the remaining monoclinic dicalcium phos-
phate dehydrate crystals (1). The interface
between the biomaterial and the bone tissue
is rough and a Howshipapos;s lacuna can be
observed (arrow; original magnification
 40).
Fig. 9. Light microscope photograph of a
toluidine blue-stained section from a bone
conduction chamber grafted with the novel
biomaterial (DTG). The photograph shows
newly formed bone growing in a lamellar
orientation (arrow heads) in direct contact
with the remaining monoclinic dicalcium
phosphate dedydrate crystals (arrow; origi-
nal magnification  40).
Table 2. Results of the histomorphometry measurements
Group AB (%) RG (%) AMT (%)
Bio-Osss 11.7  2.4n 37.2  5.5 48.9  10.0§
Control 1 5.7  1.0 – 5.7  1.0
DTG 16.7  4.9w 22.4  8.5z 39.5  4.9
Control 2 5.1  1.1 – 5.1  1.1
All data presented are mean values ( standard deviation).
nSignificantly higher than all control groups (po0.05).
wSignificantly higher than all the other groups ( po0.05).
zSignificantly higher than Bio-Osss group (po0.05).
§Significantly higher than DTG group (po0.05).
AB, augmented bone tissue; RG, Remaining unresorbed biomaterial; AMT, augmented mineral
tissue
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We attribute the high bioresorption
of DTG to the presence of DCPD and
b-TCP in its composition. b-TCP is
moderately resorbable in vivo and needs
only 12 weeks to be totally resorbed
from bone defects created in animal
models such as dogs, and 6–8 months
when implanted in humans (Wiltfang
et al. 2003, Suba et al. 2004). Further-
more, DCPD can be resorbed in vivo
even faster than b-TCP because it is
more soluble in water (Chow et al 2003,
Herron et al. 2003, Tas & Bhaduri
2004). The combination of these two
materials in the form of granules allows
the diffusion of the ioninc species as
well as the nutrients that would enhance
the resorption of the material and the
formation of new bone tissue. Bone
growth was observed in the interior of
our novel biomaterial inside the spaces
where brushite resorption had already
taken place; DTG appeared to be drilled
by new bone formation while in the
Bio-Osss grafts, bone formation took
place only around the granules.
This survey showed that both
Bio-Osss and DTG present good osteo-
conductive properties, achieving accep-
table bone augmentation. However, the
use of DTG offers faster in vivo resorp-
tion and increased bone neoformation
when compared with Bio-Osss.
Acknowledgements
The authors acknowledge financial
support from the Spanish Science and
Technology Ministry (MAT2003-
03051-C03-03) and from the Comuni-
dad Autonoma de Madrid and Universi-
dad Complutense (PR45/05-14177).
References
Acil, Y., Terheyden, H., Dunsche, A., Fleiner,
B. & Jepsen, S. (2000) Three- dimensional
cultivation of human osteoblast-like cells on
highly porous natural bone mineral. Journal
of Biomedical Material Research 52,
703–710.
Block, M. S. & Kent, J. N. (1997) Sinus
augmentation for dental implants: the use of
autogenous bone. Journal of Oral and Max-
illofacial Surgery 55, 1281–1286.
Bohner, M., Gbureck, U. & Barralet, J. E.
(2005) Technological issues for the develop-
ment of more efficient calcium phosphate
bone cements: a critical assessment. Bioma-
terials 26, 6423–6429.
Boo, J. S., Yamada, Y., Okazaki, Y., Hibino, Y.,
Okada, K., Hata, K., Yoshikawa, T., Sugiura,
Y. & Ueda, M. (2002) Tissue-engineered
bone using mesenchymal stem cells and a
biodegradable scaffold. Journal of Craniofa-
cial Surgery 13, 231–9.
Chow, L. C., Markovic, M. & Takagi, S. (2003)
A dual constant-composition titration system
as an in vitro resorption model for comparing
dissolution rates of calcium phosphate bio-
materials. Journal of Biomedical Material
Research B: Applied Biomaterials 65,
245–251.
De Boever, A. L. & De Boever, J. A. (2005)
Guided bone regeneration around non-
submerged implants in narrow alveolar
ridges: a prospective long-term clinical
study. Clinical Oral Implants Research 16,
549–556.
Donath, K. & Breuner, G. (1982) A method for
the study of undecalcified bones and teeth
with attached soft tissues. The Sage–Schliff
(sawing and grinding) technique. Journal of
Oral Pathology 11, 318–326.
Duda, M. & Pajak, J. (2004) The issue of
bioresorption of the Bio-Oss xenogeneic
bone substitute in bone defects. Annales
Universitatis Mariae Curie-Sklodowska 59,
269–277.
Giannoudis, P. V., Dinopoulos, H. & Tsiridis, E.
(2005) Bone substitutes: an update. Injury 36,
S20–27.
Herron, S., Thordarson, D. B., Winet, H., Luk,
A. & Bao, J. Y. (2003) Ingrowth of bone into
absorbable bone cement: an in vivo micro-
scopic evaluation. American Journal of
Orthopedics 12, 581–584.
Lieberman, I. H., Togawa, D. & Kayanja, M. M.
(2005) Vertebroplasty and kyphoplasty:
filler materials. Spine Journal 5 (6 Suppl.),
305S–316S.
Lundgren, A. K., Lundgren, D., Hammerle, C.
H., Nyman, S. & Sennerby, L. (2000)
Influence of decortication of the donor
bone on guided bone augmentation.
An experimental study in the rabbit skull
bone. Clinical Oral Implants Research 11,
99–106.
Lundgren, A. K., Lundgren, D., Wennerberg,
A., Hammerle, C. H. & Nyman, S. (1999)
Influence of surface roughness of barrier
walls on guided bone augmentation: experi-
mental study in rabbits. Clinical Implant
Dental Related Research 1, 41–48.
Mirtchi, A. A. & Lemaitre, J. (1989) Calcium
phosphate cements: study of the b-tricalcium
phosphate-monocalcium phosphate system.
Biomaterials 10, 475–480.
Nevins, M. (1996) Bone formation in the goat
maxillary sinus induced by absorbable
collagen sponge implants impregnated
with recombinant human bone morphoge-
netic protein-2. International Journal
of Periodontics Restorative Dentistry 16,
9–19.
Pautke, C., Vogt, S., Tischer, T., Wexel, G.,
Deppe, H., Milz, S., Schieker, M. & Kolk A, .
(2005) Polychrome labeling of bone with
seven different fluorochromes: enhancing
fluorochrome discrimination by spectral
image analysis. Bone 37, 441–445.
Rosen, B. V., Hobbs, L. W. & Spector, M.
(2002) The ultarastructure of an organic
bovine bone and selected synthetic hydroxia-
patites used as bone graft substitute materials.
Biomaterials 23, 921–928.
Schilling, F. A., Linhart, W., Filke, S., Gebauer,
M., Schinke, T., Rueger, J. M. & Amling, M.
(2004) Resorbability of bone substitute bio-
materials by human osteoclasts. Biomaterials
25, 3963–3972.
Schmid, J., Wallkamm, B., Hammerle, C. H.,
Gogolewski, S. & Lang, N. P. (1997) The
significance of angiogenesis in guided bone
regeneration. A case report of a rabbit experi-
ment. Clinical Oral Implants Research 8,
244–248.
Schwartz, Z., Somers, A., Melloning, J. T.,
Carnes, D. L. Jr, Wozney, J. M., Dean, D.
D., Cochran, D. L. & Boyan, B. D. (1998)
Ability of commercial demineralized freeze-
dried bone allograft to induce new bone
formation is dependent on donor age but
not gender. Journal of Periodontology 69,
470–477.
Slotte, C. & Lundgren, D. (1999) Augmentation
of calvarial tissue using non-permeable sili-
cone domes and bovine bone mineral. An
experimental study in the rat. Clinical Oral
Implants Research 10, 468–476.
Slotte, C., Lundgren, D. & Burgos, P. M. (2003)
Placement of autogenic bone chips or bovine
bone mineral in guided bone augmentation: a
rabbit skull study. International Journal
of Oral and Maxillofacial Implants 18,
795–806.
Stavropoulos, A., Kostopoulos, L., Nyengaard,
J. R. & Karting, T. (2004) Fate of bone
formed by guided tissue regeneration with
or without grafting of Bio-Oss or Biogran. An
experimental study in the rat. Journal of
Clinical Periodontology 31, 30–39.
Suba, Z., Takacs, D., Gyulai-Gaal, S. & Kovacs,
K. (2004) Facilitation of beta-tricalcium
phosphate-induced alveolar bone regenera-
tion by platelet-rich plasma in beagle dogs:
a histologic and histomorphometric study.
International Journal of Oral and Maxillofa-
cial Implants 19, 832–838.
Suzuki, T., Hukkanen, M., Ohashi, R., Yokoga-
wa, Y., Nishizawa, K., Nagata, F., Buttery, L.
& Polak, J. (2000) Growth and adhesion of
osteoblast-like cells derived from neonatal rat
calvaria on calcium phosphate ceramics.
Journal of Bioscience and Bioengineering
89, 18–26.
Tamimi, F. M., Lopez-Cabarcos, E., Blanco, L.,
Rueda, C., Tresguerres, I. & Torres, J. (2005)
Granulado de cemento de brushita fraguado
con a´cido glico´lico para regeneracio´n o´sea,
Spanish patent number, 200503094/5.
Tas, C. & Bhaduri, S. B. (2004) Chemical
processing of cahpo.2H2O: its conversion of
hydroxyapatite. Journal of American Cera-
mic Society 87, 2195–2200.
Taylor, J. C., Cuff, S. E., Leger, J. P., Morra, A.
& Anderson, G. I. (2002) In vitro osteoclast
resorption of bone substitute biomaterials
used for implant site augmentation: a pilot
study. International Journal of Oral and
Maxillofacial Implants 17, 321–330.
Trisi, P., Rao, W., Rebaudi, A. & Fiore, P.
(2003) Histologic effect of pure-phase
Bone augmentation in rabbit calvariae 927
r 2006 The Authors. Journal compilation r 2006 Blackwell Munksgaard
beta- tricalcium phosphate on bone regenera-
tion in human artificial jawbone defects.
International Journal of Periodontics
Restorative Dentistry 23, 69–77.
Von Arx, T., Cochran, D. L., Hermann, J. S.,
Schenk, R. K. & Buser, D. (2001)
Lateral ridge augmentation using different
bone fillers barrier membrane application.
Clinical Oral Implants Research 12,
260–269.
Wiltfang, J., Schlegel, K. A., Schultze-Mosgau,
S., Nkenke, E., Zimmermann, R. & Kessler,
P. (2003) Sinus floor augmentation with
beta-tricalcium phosphate (beta-TCP): does
platelet-rich plasma promote its osseous
integration and degradation? Clinical Oral
Implants Research 14, 213–218.
Zaffe, D., Leghissa, G. C., Pradelli, J. &
Boticelli, A. R. (2005) Histological study on
sinus lift grafting by Fisiograft and Bio-Oss.
Journal of Material Science Materials in
Medicine 16, 789–793.
Address:
Faleh Marin˜o Tamimi
Ramon y Cajal sn Facultad de Farmacia
Madrid
28040
Spain
E-mail: fdamimim@farm.ucm.es
Clinical Relevance
Scientific rationale: Bio-Osss gran-
ulate is an osteoconductive material
that has been extensively used in
bone regeneration despite its low
resorption rate in vivo. In this study,
we compare the bone augmentation
capacity of Bio-Osss with a brush-
ite-based osteoconductive and biore-
sorbable material.
Principal findings: The novel bio-
material described in this study pro-
duces more vertical bone
augmentation than Bio-Osss and
shows bioresortpion already at 4
weeks after implantation while Bio-
Osss remains practically unre-
sorbed.
Practical implications: The novel
brushite cement granules can be used
for bone regeneration as an alterna-
tive to Bio-Osss.
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A Comparative Study of 2 Methods for
Obtaining Platelet-Rich Plasma
Faleh M. Tamimi, DDS, PhD,* Santiago Montalvo, DDS, MSc,†
Isabel Tresguerres, BDS, MD, DDS,‡ and
Luis Blanco Jerez, BDS, MD, DDS§
Purpose: Double and single centrifugation are the most commonly used techniques for obtaining
platelet-rich plasma (PRP) in dentistry. In this study, we used and compared 2 methods for obtaining PRP:
double centrifugation (ACE system; Surgical Supply and Surgical Science Systems, Brockton, MA) and
single centrifugation (Nahita system; Nahita, Navarra, Spain).
Materials and Methods: Blood samples were obtained from 30 random patients. Each blood sample
was treated using the ACE system and Nahita system methods, after which the obtained material was
analyzed by flow cytometry for platelet counts and by transmission electron microscopy (TEM) for
ultrastructural analysis of the PRP gel.
Results: Platelet count analysis of the PRP obtained from both methods revealed that the ACE and
Nahita systems accomplished platelet concentrations of (336%) and (227%), respectively. The platelet
counting results obtained from the ACE system samples were more dispersed than their Nahita system
counterpart. The ultrastructural (ie, TEM) study showed considerable alterations of the platelet aggre-
gates in the ACE’s PRP, especially when the samples were not mixed in the final stage of the procedure,
whereas the Nahita aggregates always had a normal physiological appearance.
Conclusions: The ACE double-centrifugation method is able to achieve higher platelet concentrations
than the single-centrifugation Nahita system, although the results obtained by ACE were more dispersed.
Nevertheless, the ACE system provoked alterations in the PRP ultrastructure, and it was more sensitive
to small errors during preparation.
© 2007 American Association of Oral and Maxillofacial Surgeons
J Oral Maxillofac Surg 65:1084-1093, 2007
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mlatelet-rich plasma (PRP) techniques are widely used
n many surgical procedures due to PRP’s healing
roperties. Its high fibrin and growth factor concen-
ration makes PRP very useful in plastic surgery and in
topping bleeding in patients with clotting disor-
ers.1-3 Fibrin glue was first described as a surgical
dhesive by Matras4,5 in the early 1980s, who recom-
ended its use as a hemostatic and adhesive surgical
gent that could promote tissue healing. In subse-
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1084uent years, the discovery of transforming growth
actor (TGF)-1 in the platelets’ alpha granules en-
ouraged the possibility of using this blood derivative
n bone and tissue regeneration.6,7
Recently, bone regeneration has become a very
mportant subject in dental surgery. PRP, alone or in
ombination with other materials, including mem-
ranes and artificial or autologous bone grafts, are
idely used to treat patients with bone volume defi-
iencies.8-10 Moreover, PRP has been used in peri-
dontal surgery, guided tissue regeneration, and den-
al implantology to produce bone and soft tissue
egeneration in the periodontal and peri-implant re-
ions.11,12
PRP is obtained by treating blood samples (usually
aken from the same patient) with 1 of 3 methods:
ingle centrifugation, double centrifugation, or aphere-
is. In all of these methods, PRP must be calcium-
ctivated before being applied over the surgical
ite.13-17
Although the use of PRP as a bone regenerating
aterial has been widely studied,18-22 few studies
ave analyzed PRP at an ultrastrutural or cytological
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TAMIMI ET AL 1085evel to determine its actual effectiveness in providing
rowth factors for bone regeneration.23,24 Transmis-
ion electron microscopy (TEM) allows evaluation of
he cytological morphology with a very high resolu-
ion that cannot be achieved with other techniques.
o studies analyzing the ultrastructural morphology
f the PRP clots used in dentistry exist in the litera-
ure. Consequently, we initiated the present study
o compare the platelet count and ultrastructure of
RP obtained by 2 methods commonly used by den-
ists: the single-centrifugation method (Nahita system;
ahita, Navarra, Spain) and the double-centrifugation
ethod (ACE system; Surgical Supply and Surgical
cience Systems, Brockton, MA).20,21,25 The PRP sam-
les obtained by each method were analyzed by TEM
nd flow cytometry platelet counting.
aterials and Methods
Blood samples were obtained from 30 patients,
hosen randomly from the Oral and Maxillofacial Sur-
ery Department at the “Doce de Octubre” University
ospital, Madrid. The patient group comprised 19
ales and 11 females ranging in age from 17 to 84
ears (mean, 48.33  20.81 years). Informed consent
as obtained from each patient, and the hospital’s
thics Committee approved the study protocol.
Blood samples were extracted from the right basilic
eins into test tubes containing dextrose citrate acid
s an anticoagulant. To obtain platelet concentrates,
lood samples were treated with 2 different PRP
ethods using a specific centrifuge machine, the ACE
ouble-spin system (ACE 170-0002) or the Nahita sin-
le-spin system (2610). The time taken to obtain PRP
y each system was registered, and the samples were
nalyzed by the platelet-counting device and TEM for
ltrastructural analysis.
TECHNICAL DESCRIPTION
ACE Double-Centrifugation System
for PRP Processing
An 18-gauge needle (Introcam Safety 186; Braun
edical, Bethleham, PA) connected to a 3-way key
BD Conecta Plus 3; Becton Dickinson, Helsingborg,
weden) was used to extract the blood into 3 10-mL
acutainer tubes (Becton Dickinson). Each tube con-
ained 1.5 mL of an anticoagulant solution (trisodium
itrate, citrate dextrose acid), allowing a net blood
olume of 8.5 mL per tube to be obtained. The tubes
ere gently sloped several times to mix the blood
ith the anticoagulant solution.
The 3 test tubes were introduced into an ACE
entrifuge machine and subjected to a force of 160 g
1,300 rpm) for 10 minutes. In this way, the blood
as separated into a red inferior phase, containingost of the blood cells (first-centrifugation PRP), and
superior plasma supernatant phase (first-centrifuga-
ion platelet-poor plasma [PPP]). The superior PPP
ayer was aspirated away using a 5-mL syringe with a
3-mm needle and placed into a new test tube with-
ut anticoagulant. The blood derivatives obtained
rom the first test tube—first-centrifugation PPP and
rst-centrifugation PRP—were labeled samples B and
, respectively, and saved for the analysis.
The remaining contents of the other 2 test tubes
first-centrifugation PRP) were treated with a second
entrifugation, using a 400-g force (2,000 rpm) for 10
inutes, which separated the plasma into a superior
ellowish PPP layer and an inferior reddish PRP layer.
he PPP was extracted with a 5-mL syringe attached
o a 63-mm needle and labeled sample D (second-
entrifugation PPP). The 1.5 mL of PRP remaining in
he original test tube was gently homogenized by
spirating and evacuating the contents of the test tube
times, using a 5-mL syringe with a 76-mm needle.
his final homogenized sample was labeled sample E
second-centrifugation PRP). Many practitioners who
se the double-centrifugation ACE method do not mix
he plasma in the final stage; for this reason, a sample
f unmixed second-centrifugation PRP was also taken
or TEM examination.
Nahita Single-Centrifugation System
for PRP Processing
Blood was extracted into 3 5-mL citrated tubes
Venojet; Terumo MR, Tokyo, Japan) containing 0.5
L of trisodium citrate, citrate, and acid citrate dex-
rose (ACDA) as anticoagulants. The test tubes were
ently slopped until mixing of the blood with the
nticoagulant was complete. One of the 3 test tubes
as used for whole blood analysis and initial platelet
ounting (sample A). The remaining 2 test tubes were
entrifuged with a 280-g force (1,500 rpm) for 7
inutes.
After centrifugation, the plasma in the test tube was
ivided into 3 equal layers, which were placed in 3
ifferent sterile test tubes using a 500-L pipette (Na-
ita system) in an attempt to minimize turbulence
uring aspiration. The most superficial layer was
laced in the first test tube and labeled sample F
PPP). The middle layer, platelet medium plasma
PMP), was placed in the second tube and labeled
ample G. The lowest layer, which had the highest
latelet content (PRP), was placed in the third tube
nd designated sample H.
Sample Labeling
Each sample was labeled with a letter as follows:
A: Whole blood
B: ACE centrifugation system, first-centrifugationPPP
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1086 OBTAINING PLATELET-RICH PLASMAC: ACE centrifugation system, first-centrifugation
PRP
D: ACE centrifugation system, second-centrifugation
PPP
E: ACE centrifugation system, second-centrifugation
PRP
F: Nahita centrifugation system, PPP
G: Nahita centrifugation system, PMP
H: Nahita centrifugation system, PRP.
The following parameters were analyzed: platelet
ount of each sample, time needed to complete each
ethod, and ultrastructure of the obtained PRP clots.
PLATELET COUNTING AND STATISTICAL ANALYSIS
Platelet counting analysis was performed on all of the
amples using a flow cytometry device (ADVIA 120
ematology System; Bayer, Leverkusen, Germany) in
he Hematology Department of “Doce de Octubre” Uni-
ersity Hospital. Samples E and H were the most rele-
ant because they are the final products obtained by the
CE and Nahita systems, respectively. Sample C is also
nteresting, because it should be similar to sample H. For
his reason, 2 other parameters were calculated for
hese 3 samples: platelet concentration and platelet in-
rease over whole blood baseline. These values were
alculated using the following equations:
latelet increase over blood baseline

Platelet count of (PRP)
 Platelet count of whole blood
Platelet count of whole blood
nd
latelet concentration

Platelet count of PRP
Platelet count of whole blood
he platelet increase over whole blood baseline value
s better for describing the increase in platelet counts.
evertheless, the platelet concentration value is the
ore commonly used value in the literature; there-
ore, it was calculated for comparing our results with
he data published by other authors. The data thus
btained were analyzed using a parametrical Student
test with SPSS software (SPSS Inc, Chicago, IL).
Ultrastructure Analysis (TEM)
Preparing, cutting, and visualizing the samples
ere done using the following devices and reagents:
ltramicrotome (Ultra Cut-E; Reitchert-Jung, Wetzlar,
ermany); resin trimmer (Ultratrim; Reitchert-Jung);
nife Maker (Reitchert-Jung); transmission electron
icroscope (JEOL 1010; JEOL, Tokyo, Japan), NaCl SSigma-Aldrich, Schnelldorf, Germany); KCl, KH2PO4
Merck, Whitehouse Station, NJ); Na2HPO4 (Probus,
arcelona, Spain); CaCl2 solution (Roche, Basel, Swit-
erland); Glutaraldehyde (Tosimis; Rockville, MD);
purr’s Taab embedding resin (Taab Laboratories,
erkshire, UK), and Eppendorf tubes (Daslab; Nirco
A, Barcelona, Spain).
Plasma samples were activated with a 0.0025 M
aCl2 solution and were kept at body temperature for
0 minutes, accomplishing complete clot jellification.
lot fragments were fixed with glutaraldehyde solu-
ion 25%, protected from the light with an aluminum
oil, and stored in a refrigerator for 6 hours at 4°C.
amples were then washed with a phosphate-buff-
red saline (PBS)(pH 7.4; 4°C) every 30 minutes for a
otal of 5 times and cut with a surgical blade n°15 into
mall fragments that were placed in Eppendorf tubes.
he PBS was carefully removed and replaced by a 1%
smium tetraoxide solution that was withdrawn 1.5
ours later, after which the samples were washed
ith tri-distilled water every 15 minutes a total of 4
imes. Because osmium tetraoxide is very toxic, all of
he contaminated materials were disposed of in safe
ontainers. At this point, samples were dehydrated by
lacing them in increasing concentrations of acetone
olutions: 30%, 50%, 70%, 80%, 90%, and 95%. All
amples were kept 30 minutes in each concentration
efore being moved to the next one. Then they were
laced in pure acetone for 60 minutes to achieve
omplete dehydration. During this process, each ac-
tone solution was renewed every 15 minutes.
After dehydration, samples were imbibed with dif-
erent Spurr’s resin-to-acetone solution ratios. First, a
esin-to-acetone solution of 1:3 was applied for 1
our, followed by a 1:1 resin-to-acetone solution for
nother hour and then a 3:1 resin-to-acetone solution
or 2 hours. Finally, the samples were introduced in a
00% resin for 10 hours, after which the 100% resin
as renewed, and the resin-imbibed samples were
laced in an incubator at 60°C for 3 days to complete
he resin polymerization.
The samples containing resin-polymerized blocks
ere removed from the Eppendorf tubes and
rimmed into adequate parallel shapes with the Ultra-
rim device. A microtome blade was prepared using
he Knife Maker device, and the samples were cut
nto preliminary 75--thick slices. These slices were
yed with methylene blue for assaying with light
icroscopy. When preliminary slices were satisfac-
ory, 50-nm-thick cuts for TEM were made with the
ltramicrotome. These cuts for TEM were fixed with
ranilium citrate 2%, and contrast was prepared with
ead citrate. Finally, the samples were placed on the
tubbs for TEM analysis.
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TAMIMI ET AL 1087esults
PLATELET COUNTING
The average hematocrit and initial whole blood
latelet count (sample A) of the patients included in
he study were 36.68  6.71% and 187,233  57,658
latelets/mm3, respectively. Platelet counts for sam-
les C (426,000  134,932 platelets/mm3), E
630,200  269,969 platelets/mm3) and H (425,600
152.111 platelets/mm3), were higher than that for
ample A (Tables 1 and 2, Fig 1).
TEM micrographs showed regular aggregations of
early empty oval-shaped platelets with intact cell
embranes, slightly touching each other at the center
f the aggregate. Inside the platelets, mitochondria,
n open canalicular system, and very few dense and
lpha granules were seen. All organelles were ori-
nted toward the center of the aggregate. In a similar
anner, platelet secretions were also concentrated in
he middle of the aggregate. Some myelin bodies were
oted, caused by cell injury and the glutaraldehyde-
xing process. There were some erythrocytes and
laments of polymerizing fibrin extending outward
rom the center of the aggregate (Fig 2).
Sample C: ACE First-Centrifugation PRP
Compared with sample B, the sample C micrograph
howed an obvious increase in the concentration of
Table 1. PLATELET COUNTING OF THE SAMPLES
Sample A B C
latelets/L (mean) 187.230 173.960 426.000
tandard deviation 57.650 72.010 134.930
Platelet counting of the samples: A, whole blood; B, ACE centrifu
entrifugation PRP; D, ACE centrifugation system, second centrifu
ahita centrifugation system, PPP; G, Nahita centrifugation system
amimi et al. Obtaining Platelet-Rich Plasma. J Oral Maxillofac
Table 2. COMPARISON BETWEEN ACE AND NAHITA
SYSTEMS IN THE FOLLOWING PARAMETERS:
PLATELET RICH PLASMA CONCENTRATION, PLATELET
INCREASE OVER WHOLE BLOOD BASELINE, BLOOD
VOLUME NEEDED AND TIME NEEDED
Parameters
Double
Centrifugation
(ACE system)
Single
Centrifugation
(Nahita system)
C E H
latelet concentration (227%) 352% 232%
latelet increase over
whole blood
baseline (127%) 236% 128%
lood volume 25.5 mL 13.5 mL
ime needed 25 min 12 minT
S
amimi et al. Obtaining Platelet-Rich Plasma. J Oral Maxillofac
urg 2007.latelets in each aggregate as well as in the amount of
brin (Fig 3).
Sample E: ACE Second-Centrifugation PRP
As shown in Figure 4, in the unmixed samples,
umerous packed red blood cells (PRBCs) sur-
ounded the platelet aggregates. Despite being de-
ormed and compacted by centrifugation, these cells
aintained a continuous space between each other,
ue to the electrical repulsion of the adjacent posi-
ively charged membranes. Platelet aggregates had a
ompacted round shape that made it difficult to spot
he platelets, although their membranes, mitochon-
ria, and open canalicular system remained intact.
latelets showed a high degree of activation caused
y the loss of membrane potential, marked by such
eatures as high-grade depletion of alpha and dense
ranules, formation of vacuoles, and prolongation of
seudopodia between the red cells. Most fibrin ag-
lomerates were totally trapped within platelet aggre-
ates, although some agglutinated fibrin was observed
utside the aggregate in the spaces between the
RBCs. Fibrin agglomerates did not touch the cell
embranes. The sample showed higher amounts of
brin and platelets compared with the other PRP
IGURE 1. Relationship between blood derivative sample and plate-
et concentration.
D E F G H
3.930 630.200 196.300 222.860 425.600
1.580 269.960 73.120 81.690 152.110
system, first centrifugation PPP; C, ACE centrifugation system, first
PPP; E, ACE centrifugation system, second centrifugation PRP; F,
H, Nahita centrifugation system, PRP.
007.2
1
gation
gation
, PMP;amimi et al. Obtaining Platelet-Rich Plasma. J Oral Maxillofac
urg 2007.
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1088 OBTAINING PLATELET-RICH PLASMAamples. Some lymphocytes were seen in the clot,
nd these had increased cytoplasm due to activation
f the immune response. This phenomenon is com-
atible with an increased synthesis of cytokines by
hite blood cells, which could prematurely activate
latelet degranulation, causing a premature loss of
rowth factor proteins in the PPP layer. On the other
and, when the sample was mixed with the pipette,
ormal heavy populated platelet aggregates were free
f PRBCs (Fig 5).
Sample F: Nahita Single-Centrifugation PRP
This sample exhibited few platelet aggregates, with
ome fibrin threads that polymerized inside the aggre-
ate projecting outward. Platelets were rounded with
IGURE 2. A, Sample B, 5000. The image shows some erythr
10,000. Platelets are touching each other at the aggregate cente
oncentrated in the middle of the aggregate. Polymerizing fibrin fil
40,000, ACE first-centrifugation PRP. The micrograph shows nearl
rrow), remnants of the open canalicular system (2 arrows), and som
amimi et al. Obtaining Platelet-Rich Plasma. J Oral Maxillofacn intact continuous membrane that contained some urganelles, granules, irregular vacuoles, and electro-
ense bodies (probably glycogen). All of these cellular
odies were concentrated in the platelet aggregate
ole (Fig 6).
Sample H: Nahita Single-Centrifugation
PRP Layer
This sample also contained some fibrin threads and
rythrocytes along with the platelet aggregates,
hich had less fibrin and fewer platelets compared
ith the double-centrifugation PRP samples. Inside
he platelets, dense canalicular system, mitochondria,
ell pseudopodia, and electrodense bodies were seen.
ut platelets were nearly absent in most of the gran-
les, with only very few alpha granules remaining
(1 arrow), regular platelet aggregations (2 arrows). B, Sample B,
n, leaving their outer surfaces free (1 arrow). Platelet secretions are
prolongate out of the aggregate center (2 arrows). C, Sample B,
oval-shaped platelets with intact cell membranes. Mitochondria (1
n bodies are noted (3 arrows).
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Surg 2ndelivered (Fig 7).
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TAMIMI ET AL 1089iscussion
PLATELET COUNTS
Due to the increasing use of implants and the con-
equent need for sufficient osseous tissue, more effi-
ient bone graft techniques are being investigated.
ne of the more recent advances in this area is the
se of autologous platelet gel to promote healing and
egeneration of soft and hard tissues. This gel, a com-
ination of PRP and calcium ions, was first used as a
ealing, homeostasis, and wound healing promotion
aterial.4
Marx et al19 demonstrated that the use of PRP
echniques in surgery produce an increase in platelet
oncentration, and their application on bone defects
IGURE 3. A, Sample C, 4000. The micrograph shows a platelet
ggregate (1 arrow) and fibrin filaments (2 arrows). B, Sample C,
120,000. The micrograph shows cell membrane integrity, with an
vident mitochondria (1 arrow) and open canalicular system (2 ar-
ows) within platelets.
amimi et al. Obtaining Platelet-Rich Plasma. J Oral Maxillofac
urg 2007.ncreases bone formation and density within 6 tonths, enhancing osseous quality and quantity.
hese authors also proved the presence of 3 growth
actors (platelet-derived growth factor [PDGF], TGF-
1, and TGF-2) with their respective membrane
arkers in the PRP.
According to Marx,22 the working definition of PRP
s a concentration of 1,000,000 platelets/L in a 5-mL
olume of plasma (PRP concentration, 338%). Lower
oncentrations are reportedly unreliable in enhancing
ound healing, although higher concentrations have
ot been shown to further enhance wound healing.
arx et al19 stated that a double-centrifugation tech-
ique is necessary to truly concentrate platelets from
utologous blood. The first spin separates the red
lood cells from the plasma, which contains the plate-
ets, white blood cells, and clotting factors. The sec-
nd spin finally separates the platelets and white
lood cells, along with a few red blood cells, from the
lasma. This “soft spin” produces a PRP free from the
bstruction due to a large number of red blood cells.
arx et al19 stated that obtaining PRP with a single-
pin technique would produce not a true PRP, but
ather PRP–PPP mixture with a disappointingly low
latelet count.
On the other hand, Anitua21,26 supported using a
ingle-spin technique (although he did not report the
latelet concentrations obtained by this procedure).
ther authors have reported obtaining platelet con-
entrations of 356% using the single-spin technique.27
In this study, the PRP concentrations of platelets
btained by both techniques after the first centrifuga-
ion were quite similar, 232.4% for the Nahita system
nd 227.8% for the ACE system. The PRP concentra-
ions obtained from the ACE second-centrifugation
rotocol revealed an increased platelet concentration
f 352%. These results are similar to the minimum
38% proposed by Marx,22 but well below the 713%
entioned by Gonshor in his study of the ACE sys-
em.25
Recent studies have confirmed that double-centrif-
gation techniques can yield concentration values
qual or higher than those cited by Marx. Weirbrich
t al23,24 obtained increases of 370% using the
urasan system (Curasan AG, Kleinostheim, Ger-
any) and 761% with the PCCS system (3i Implant
nnovations, Inc, Palm Beach, FL) in a comparative
tudy between the 2 protocols. In other studies, Ap-
el et al28 managed to obtain a concentration of
501%) with the PCCS system and (1170%) with the
urasan system.
The platelet concentrations obtained with ACE
echnique were superior to those obtained by the
ahita system. This finding was expected because the
CE system uses a double-centrifugation technique.
evertheless, the ACE results were more dispersed
han the Nahita results; thus, occasionally the concen-
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1090 OBTAINING PLATELET-RICH PLASMArations obtained by the Nahita system were higher
han those obtained with the ACE system for the same
atient. This lack of precision could be due to the
elicacy of the ACE technique. Furthermore, the ACE
ystem consumed more time and required larger vol-
mes of blood.
ransmission Electron Microscopy
Using TEM for examining blood derivative clots
evealed several phenomena regarding the PRP ultra-
tructure that would not have been detected using
he more common techniques of immunohistochem-
stry or light microscopy. Furthermore, TEM can be
ven more cost-effective than inmunohistologic anal-
IGURE 4. A, Sample E (nonmixed sample), 5000. The microgra
rrow). Red blood cells maintain a continuous space between eac
gglomerates are agglutinated within the platelet aggregates. Fibrin a
ample),10,000. This figure shows round-shaped deformed platelet
(nonmixed sample), 40,000. Although the platelet membranes re
itochondria (2 arrows), and an open canalicular system (3 arrows)
amimi et al. Obtaining Platelet-Rich Plasma. J Oral Maxillofacsis, such as enzyme-linked immunosorbent assay or bow cytometry techniques, because it does not re-
uire expensive immunologic markers.
Comparing the micrographs of the samples ob-
ained with the 2 PRP techniques revealed that in
oth techniques, platelets had liberated nearly all of
he alpha and dense granules’ contents. We con-
luded that a period of 30 minutes of Ca incuba-
ion was easily sufficient to make the platelets empty
ll of their contents. Despite the centrifugation pro-
edures, most platelet organelles could be differenti-
ted in all of the samples, and several signs of platelet
unction and vitality, such as intact membranes and
eaction to Ca by pseudopodia prolongation and
egranulation, could be seen. Therefore, it could be
tated that centrifugation did not harm platelets in
s numerous PRBCs (2 arrows) surrounding the platelet aggregate (1
. Platelet aggregates have a compacted appearance. Most fibrin
rates are not touching the PRBC membranes. B, Sample E (nonmixed
w) and lymphocytes with increased cytoplasm (2 arrows). C, Sample
ntact, they are compacted and difficult to spot. Vacuoles (1 arrow),
n. Fibrin (black patches) is seen within platelet aggregates.
007.ph show
h other
gglome
s (1 arro
main i
are seeoth the single- and double-centrifugation techniques.
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TAMIMI ET AL 1091ther authors have confirmed this fact, explaining
hat it occurs due to the low gravity force used in both
echniques.29
In the double-centrifugation ACE technique, higher
mounts of erythrocytes were observed. When mix-
ng of the PRP clot was not performed, deformed
RBCs were predominant. Furthermore, there was no
irect contact between the PRBCs. This phenomenon
as explained in other works by the membrane-pos-
tive charge repulsion produced through the sodium
otassium pump.30 Therefore, the PRBCs maintained
heir membrane potential and vitality despite the cen-
rifugation procedure. On the other hand, platelets
ould adhere to each other and to the erythrocytes
ue to membrane depolarization.31
Polymerized fibrin projected outward from the
latelet aggregate in all samples except the nonmixed
ample E, in which fibrin was trapped within the
latelet aggregates. This variation can be explained by
he repulsion of the positively charged fibrinogen
roteins from the also positively charged erythrocyte
embranes. This phenomenon could be accentuated
y the RBCs’ anaerobic metabolism. Due to their lack
f mitochondria, RBCs produce high amounts of lac-
ic acid under in vitro conditions, resulting in decreas-
ng media pH. Because the isoelectric points of the
ifferent fibrinogen proteins range between 4 and 7,
cidification of the media will result in positively
harged fibrinogen chains.32 A fibrin-positive charge
ill repel it from the RBC membrane, causing agglu-
ination and entrapment of fibrine inside the clot. In a
imilar manner, growth factors with basic isoelectric
oints, such as PDGF (pH 10-11) and TGF-1 (pH
IGURE 5. Sample E (mixed sample), 8000. The figure shows
ome normal erythrocytes (1 arrow) and a heavy populated platelet
ggregate (2 arrows) with fibrin threads spreading from it (3 arrows).
amimi et al. Obtaining Platelet-Rich Plasma. J Oral Maxillofac
urg 2007..5), would also have a positive charge in this acidic
T
Snvironment that could repel them from the RBC
embrane, compromising their availability for tissue
egeneration.33,34 Furthermore, activated lympho-
ytes were detected in sample E (nonmixed). Special
ttention should be paid to the fact on activation,
eukocytes release cytokines that activate the platelets
rematurely. Platelets can also be activated by exces-
ive pipetting, centrifugation of the samples, the use
f metallic or glass instruments, the use of a tourni-
uet over the vein to be punctured for blood extrac-
ion, or when not eliminating the first 2 mm of the
xtracted blood.35,36 This premature platelet activa-
ion leads to an early release of growth factors. So
hen the blood sample is centrifuged, the growth
actors will move to the most superior part. This way,
he obtained PRP will be poor in growth factors.
ugrillon et al37 reported that the number of platelets
IGURE 6. A, Sample F, 10,000. The micrograph shows a plate-
et aggregate (2 arrows) and very few fibrin threads (1 arrow).
, Sample F, 50,000. Rounded platelets with an intact continuous
embrane holding organelles are seen.amimi et al. Obtaining Platelet-Rich Plasma. J Oral Maxillofac
urg 2007.
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1092 OBTAINING PLATELET-RICH PLASMAs not always proportional to the growth factors’
uantity, so more attention should be paid to the
uality of PRP than to the number of platelets con-
entrated. Their study proved that the TGF-1 and
latelet concentration are proportionally related to
he centrifugation forces when these forces are less
han 800 g. Above 800 g, the TGF-1 becomes in-
ersely related to the centrifugation force. In our
tudy, the centrifugation forces were 280 g for the
ahita system and 160 g and 400 g for the first and
econd spins, respectively, of the ACE system. These
forces are far below the 800 g reported by Dugrillon
t al37; thus, both Nahita and ACE g forces are within
he safe limit, although a slight increase could be
erformed in the g forces to get higher concentra-
ions of platelets, which needs to be confirmed with
latelet viability tests in future studies.
To summarize our findings, both the Nahita (single-
IGURE 7. A, Sample H, 10,000. A platelet aggregate (1 arrow
gure shows a platelet aggregate. The platelet membranes remain inta
, 120,000. The figure shows a platelet with its dense tubular sys
amimi et al. Obtaining Platelet-Rich Plasma. J Oral Maxillofacentrifugation) and ACE (double-centrifugation) sys- tems are easy to use, can concentrate platelets with-
ut damaging them despite the centrifugation process
hat the platelets suffer, and are valid for bone and
issue regeneration. Nevertheless, the ACE system
chieves higher platelet concentrations and larger
latelet aggregates than the Nahita system, although
he Nahita system is simpler and less time-consuming
han ACE system. On the other hand, PRBCs and fibrin
gglutination were found in ACE double-centrifugation
RP samples in which final mixing was not per-
ormed. Future studies should use immunohistochem-
stry techniques to confirm that this fibrin agglutina-
ion phenomenon can also affect platelet growth
actors. Nonetheless, mixing of the final clot obtained
y the ACE double-centrifugation technique is an im-
ortant step that should not be skipped. TEM high-
esolution analysis for blood elements has proven to
e a very accurate and useful tool for PRP ultrastruc-
nded by few erythrocytes (2 arrows). B, Sample H, 40,000. The
organelles, such as alpha granules, easily seen (1 arrow). C, Sample
arrow), and an alpha granule (2 arrows).
007.) surrou
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tem (1ural investigations.
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Effect of Solely Applied Platelet-Rich Plasma on
Osseous Regeneration Compared to Bio-Oss®:
A Morphometric and Densitometric Study on
Rabbit Calvaria
Jesús Torres, DDS, PhD;* Faleh M. Tamimi, BDS, PhD;† Isabel F. Tresguerres, MD, DDS,PhD;‡
Mohammad H. Alkhraisat, BDS, MPhil;§ Ameen Khraisat, BDS, PhD;¶ Enrique Lopez-Cabarcos, BSc, PhD;**
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ABSTRACT
Background: The use of platelet-rich plasma (PRP) in bone augmentation procedures is well documented; however, the
exact benefit of this material is not yet established.
Purpose: This study aimed to evaluate the benefits of using PRP, when only used, and compare it to Bio-Oss® (Geistlich
Biomaterials, Wolhusen, Switzerland) in vertical bone augmentation capacity.
Materials andMethods: The study was performed in calvaria of eight adult female New Zealand rabbits using titanium bone
conduction cylinder. Two titanium cylinders were fixed into perforated slits made on the parietal bone of each rabbit. On
each rabbit, one chamber was grafted with Bio-Oss, and the contralateral was filled with PRP. Animals were sacrificed 4
weeks after intervention and biopsies were taken. Densitometric, histological, and histomorphometric analyses were
performed to evaluate bone mineral density, vertical bone augmentation, and remaining graft volume, respectively.
Statistical analyses were performed with Mann–Whitney test, using a significance level of p < .05.
Results: Densitometric and histomorphometric data analysis revealed that mean bone mineral densities and bone augmen-
tation were significantly lower in the cylinders treated with PRP (p < .0001) 4 weeks after implantation.
Conclusion: This study showed no beneficial effect of using PRP on osseous regeneration. In addition, it was emphasized
that Bio-Oss presents good osteoconductive properties by achieving suitable bone volume values.
KEY WORDS: Bio-Oss, bone regeneration, PRP, rabbits
Ideal bone graft material should combine osteocon-ductive, osteoinductive, and osteogenic properties;
however, only autologous bone grafts gather all these
three properties.1 Several osteoconductive biomaterials
such as allografts, xenografts, and alloplastic grafts have
been evaluated for bone regeneration purposes.2–9 Bio-
Oss® (Geistlich Biomaterials, Wolhusen, Switzerland)
xenografts are hydroxyapatite granules from bovine
origin that have been extensively used in bone augmen-
tation procedures.3–6 The lack of osteoinductive proper-
ties in this biomaterial encourages researchers to find
ways for improving its in vivo behavior. Recently, the use
of growth factors for stimulating bone regeneration
raised great interest.10–16 Multiple studies had pointed
out the advantages of using platelet-rich plasma (PRP)
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for stimulating bone regeneration.17,18 PRP is a platelet
concentrate easily obtained by centrifugation of autolo-
gous blood and enriched with growth factors. These
growth factors were described to be released from
alpha granules when platelet activation is induced by
Ca ions from the extracellular media. Platelet growth
factors play an important role in angiogenesis and tissue
regeneration by controlling cell migration, differen-
tiation, and proliferation.19–21 PRP had been used in
combination with other biomaterials such as bovine
hydroxyapatite or autologous bone grafts.22–25
However, there might be possible benefits from
using PRP, especially when it is not combined with other
biomaterials. Therefore, the present study aimed to
evaluate the benefits of using PRP alone, and compare it
to Bio-Oss, as control, in vertical bone augmentation
capacity.
MATERIALS AND METHODS
In this animal study, the protocol was approved by the
ethical committee for animal experiments of Com-
plutense University of Madrid (UCM). Experiments
were conducted in accordance with the guidelines laid
down by the European Communities Council Directive
of November 24, 1986 (86/609/EEC), and adequate
measurements were taken to minimize pain and dis-
comfort to animals.
Eight healthy 6-month-old female New Zealand
rabbits of about 3.5 kg were used in this study. The
animals were accommodated in the official stable for
animal assays of the UCM at 22 to 24°C with 55 to 70%
humidity, light cycles of 12 hours, and air renewal 15
times per hour.
Preparation of PRP and Platelet Counting
All rabbits were anesthetized with an intramuscular
dose of 0.75 mg/kg ketamine (Imalgene 1000®, Rhone
Merieux, Toulouse, France) and 0.25 mg/kg xilacine
(Rompun®, Bayer, Leverkusen, Germany). Immediately
before surgery, 10 cc of whole blood was withdrawn via
ear venous aspiration into 4.5 cc test tubes. Directly, it
was mixed with a 3.8% sodium citrate solution at a ratio
of 1 cc sodium citrate solution to 5 cc whole blood,
achieving anticoagulation through calcium binding. The
blood was then centrifuged with a Nahita® 280G centri-
fuge (AUXILAB S.L., Navarra, Spain) into three basic
components: red blood cells (RBCs), PRP, and platelet-
poor plasma (PPP). Because of differential densities, the
RBC layer usually presents at the lowest level, the PRP
layer in the middle, and the PPP layer at the top. A
pipette (Gilson, Villiers-le-Bel, France) was used to sepa-
rate each layer from the less dense to the denser. There-
fore, PPP was separated first (about 2.25 cc) and PRP
second (about 0.9 cc), leaving the residual RBCs (about
2.25 cc).
Platelet counting of the obtained PRP was measured
with a flow cytometry device (ADVIA 120, Hematology
system, Bayer, Leverkusen, Germany). Before its surgical
application, PRP (0.2 mL) was activated with a 30%
CaCl2 solution. The preparation of PRP was performed
simultaneously during the surgical procedures.
Surgical Procedure
In the present study, titanium bone conduction cylinder
method was applied. The titanium cylinders (Laborato-
rios Aragoneses s.a., Madrid, Spain) had an inner rough
surface with dimensions of 4 mm height, 0.5 mm thick-
ness, and 9 mm diameter. Upon collecting the PRP,
animals were placed in sternal recumbency, the head was
shaved, and the cutaneous surface was disinfected with
povidone iod solution prior to the operation. Surgical
steps followed in this protocol were similar to those
applied in a previous study.26 The calvaria bone surface
was exposed through a skin incision of approximately
4 cm in length over the linea media. The defects were
made on each side of the median sagittal suture without
crossing it. A titanium bone conduction chamber was
created by fixing a 4-mm-high titanium ring on each
slit, and slightly removing the cortical bone surface
surrounded by the ring with a rounded burr in order
to promote bone regeneration. On each rabbit, one
chamber was grafted with Bio-Oss and the contralateral
was filled with PRP. Closure and relocation of perios-
teum, subcutaneous tissues, and skin were achieved
according to a previous protocol.26 Terramicina® (Pfizer,
Madrid, Spain) in water was given for 7 days as a post-
operative antibiotic. The animals were sacrificed 4 weeks
after the intervention with an overdose of sodium pen-
tobarbital IV (Dolethal®, Vétoquinol, Lure, France).
In postmortem phase, tested bone sites were har-
vested and samples were then preserved fixed in form-
aldehyde 10% buffer solution at pH 7.0.
Densitometry
Densitometry for the analysis of bone mineral density
(BMD) was achieved on the calvaria blocks using the
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XR-26 Norland® densitometer (Norland Corp., Fort
Atkinson, WI, USA). A bone area of 0.5 ¥ 0.5 cm2 was
analyzed inside both the PRP and the Bio-Oss control
cylinders with an exploring resolution of 1.0 ¥ 1.0 mm2,
a measuring resolution of 0.5 ¥ 0.5 mm2, and an explo-
ration speed of 40 mm/s. BMD was then calculated.26
Histology and Histomorphometry
Sample dehydration, embedding, sectioning, and
staining were performed according to a previous
protocol.26–28 The histological evaluation of bone neo-
formation was carried out by means of optical micros-
copy. Light micrographs (at magnification ¥6) of the
biopsy slices were captured with a digital camera and
analyzed with the histomorphometry software MIP-4
(Digital Image System, Barcelona, Spain). Six randomly
selected slices were analyzed for each biopsy sample. The
area inside the cylinder was included for histomorpho-
metric evaluation, while the original cortical bone and
the area outside the cylinder were excluded. The already-
existing bone was lamellar, while the regenerated bone
was woven and grew inside the cylinder so both types of
bone could be easily differentiated in the histological
observations.
Total sample volume, newly formed bone, and
remaining graft (RG) volume were measured in each
cylinder. Collected measurements would enable cal-
culating the average percentage of augmented bone
volume (BV) formed in chamber and percentage
volume of the RG material. The total of BV and RG is the
augmented mineralized tissue (AMT).26
Statistical Analysis
Statistical analyses were achieved using statistical soft-
ware package (SPSS 7.0, Chicago, IL, USA) for analyzing
densitometry and histomorphometric measurements by
Mann–Whitney test (p < .05).
RESULTS
No operative or postoperative complications were noti-
ced, and no animal loss occurred before scarification.
Platelet Counting
Platelet counts confirmed that the PRP preparation
technique used in this study produced a source of
highly concentred platelets. The average peripheral
blood platelet count was 144,000/mm3 with a range
from 70,000 to 260,000. The average PPP count was
45,000/mm3 with a range of 10,000 to 50,000. The
average PRP platelet count was 1,050,000/mm3 with a
range of 625,000 to 1,465,000.
Densitometry
BMD mean values of PRP and Bio-Oss chambers were
0.317 1 0.051 and 0.128 1 0.024 g/cm2, respectively.
High statistical significant difference (p < .0001) was
revealed as Bio-Oss had significantly high mineral
density (Figure 1).
Histology
No inflammatory reactions were observed in the histo-
logical slices in bone conduction cylinders for both
tested materials. In both groups, bone growth was more
pronounced on the titanium walls and occurred from
the original bone surface, but not from the periosteum.
This was observed more in Bio-Oss cylinders (Figure 2).
In cylinders grafted with PRP, bone formation was
scarce, and few isolated newly formed trabeculae were
seen on the external cortical surface. The trabeculae
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Figure 1 Box-plot chart of bone mineral density values of
inside the cylinders.
Figure 2 Higher degree of new bone formation and lesser
numbers of interconnecting bone trabeculae noticed in samples
of platelet-rich plasma (left cylinder) compared to those grafted
with the Bio-Oss (right cylinder) (original magnification ¥ 2).
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were often connected to the original bone surface. No
osteoblast activity was observed (Figure 3).
Regarding chambers grafted with Bio-Oss, a large
number of the implanted granules was observed distrib-
uted over the whole specimen area. Acidophilic Bio-Oss
was dyed gray-blue with TB. Bio-Oss particles present
lacunae free from osteocytes because of their animal
origin; nevertheless, their artificial shape differentiates
them from any bone trabeculae that might be growing
around. Bio-Oss granules were mostly surrounded by a
thin layer of fibrous tissue, especially at the medium and
upper tiers, while in the lower tier (corresponding to
the area in contact with calvaria) bone trabeculae were
observed surrounding the smooth surface of the
Bio-Oss particles (Figure 4). Bone regeneration was
observed from the external surface of the cortical bone
to approximately one-third of the height of the cylinder
confirming the osteoconductive properties of Bio-Oss
(Figure 5). However, typical signs of biomaterial resorp-
tion such as osteoclasts forming Howship’s lacunae on
its surface, etching, pits, or resorptive trail formation
could not be identified on Bio-Oss granules.
Histomorphometry
The data obtained from histomorphometry analyses are
shown in Table 1. Obtained BV, RG, and AMT values
were significantly lower for PRP chambers (p < .0001).
DISCUSSION
A clear differentiation was revealed by the result of the
present study between the effect on osseous regenera-
tion of solely applied PRP and Bio-Oss. The investi-
gated densitometric and histomorphometric parameters
showed statistically significant high influence of the
control (Bio-Oss) when compared with PRP (see
Figure 1 and Table 1).
In recent studies, PRP had been found to influence
bone matrix protein expression during early stages of
bone regeneration, and a significant increase in bone
formation occurs 2 weeks after its implantation.29,30 A
possible role in local regulation of fracture healing and
bone regeneration was suggested and that might be
probable because of the synergic effect of growth
Figure 3 Few isolated newly formed trabeculae were seen on
the external cortical surface (original magnification ¥ 10).
Figure 4 Micrograph of bone conduction chamber grafted with
Bio-Oss showing the second half of the bone conduction
chamber away from the original bone surface. Bio-Oss granules
(*) are surrounded mainly by fibrous tissue (+) and scarce
newly formed bone (arrowhead) (original magnification ¥ 10).
Figure 5 Bone regeneration was observed from the external
surface of cortical bone to approximately one-third of the
height of the cylinder (original magnification ¥ 3).
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factors present in the alpha granules of PRP.31–33 Simi-
larly, several authors claimed PRP capacity to improve
bone regeneration quality and quantity.17 It has been
suggested that PRP improves bone regeneration in its
early phases, between 3 and 6 weeks after implanta-
tion.34 In addition, it has recently been reported that
PRP alone could help in increasing bone augmentation
in sinus lifting procedures.35 However, in this experi-
ment, the aforementioned could not be confirmed
when PRP was solely applied. The present study came
in agreement with other recent studies that reported
no benefits from using PRP on bone regeneration in
bicortical defects on rabbit calvaria.30,36 It was reported
that PRP has no effect in early bone healing, and its
combination with collagen shows no benefits on bone
regeneration over using collagen alone.30 Moreover, in
another study, PRP was combined with collagen
sponges and used to fill critical size defects on rabbit
calvaria, but no significant improvement on the bone
regeneration was observed.36 Yamada and colleagues37
stated that PRP is only useful when it is used combined
with mesenchymal cells; otherwise, it has no better
effect than controls.
Nevertheless, the histomorphometric results of the
present study reveal little bone formation in PRP
groups. These results resemble those reported elsewhere
in the literature, where only a 6.24% augmented BV was
obtained after 4 weeks of locally applying peripheral
blood in a similar-guided bone regeneration model.38
The BV values obtained in samples treated with Bio-Oss
were comparable to that found in the literature where
Bio-Oss was grafted into silicone cylinders on rat’s cal-
varia (18.1%),39 or in titanium cylinders on rabbits’ cal-
varia (11.726 and 19.9%27) (see Table 1).
Most of the animal studies that evaluate bone
regeneration obtained by using PRP were done in
critical-sized defect models.40,41 In the evaluation of
osteoconductive materials, the defect created should be
large enough to challenge the adjacent bone with a
space that can hardly fill spontaneously. However, the
effects of growth factors on bone conductive materials
are usually seen at an early stage during bone
ingrowth. It is then difficult to find the right time to
measure these effects, if new ingrown bone rapidly
filled the defect.42 The “bone conduction chamber” (or
cylinder) appeared to be a useful tool for quantifying
bone regeneration under the most variable conditions
in both rats, goats, and rabbits.27,41,42 This bone
chamber is unlikely to be completely filled with bone.
Therefore, the effects of growth factors, processing
of bone and biomaterials within these chambers, can
be evaluated as differing final amounts of bone are
formed. Moreover, using bone conduction chambers,
vertical bone augmentation obtained by tested bioma-
terials can be evaluated.
Several authors consider that a 4-week period of
implantation is enough time to observe angiogenesis
and bone formation in several animal models, including
rabbits, where hydroxyapatite polymers or brushite were
grafted into bone.26,38,43,44 In the present experiment, his-
tological changes that occurred in grafted areas during
the 4 weeks of implantation were pronounced and
permit to evaluate the differences in bone regeneration
capacity of both assayed biomaterials.
Regarding signs of biomaterial resorption such as
osteoclasts forming Howship’s lacunae on its surface,
etching, pits, or resorptive trail formation could not be
identified on Bio-Oss granules. From the present obser-
vations, it can be inferred that after 4 weeks in rabbits’
calvaria, Bio-Oss resorption did not take place.
CONCLUSIONS
Within the limits of the present study, it can be con-
cluded that no beneficial effect of using PRP on osseous
regeneration as it was solely applied. In addition, it was
emphasized that Bio-Oss presents good osteoconductive
properties by achieving suitable BV values.
TABLE 1 Results in Percentage of Histomorphometric Analysis for Both
Tested Materials
Tested Material BV % (1SD) RG % (1SD) AMT % (1SD)
PRP 6.24 (11.87) 0.00 6.24 (11.87)
Bio-Oss 13.18 (14.09) 35.31 (16.48) 46.81 (110.55)
AMT = augmented mineralized tissue; BV = bone volume; PRP = platelet-rich plasma; RG = remaining
graft.
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1. El cemento granulado de brushita es más reabsorbible y genera más hueso que la 
hidroxiapatita de origen bovino. 
 
2. El diseño de materiales basados en cementos fosfocálcicos dopados, mejora sus 
propiedades biológicas. 
 
3. La administración tópica de GH produce un aumento de la neoformación ósea y 
mejora el índice de contacto hueso-implante. 
 
4. Para la obtención de plasma rico en plaquetas parece más eficaz la técnica de 
centrifugado simple. 
 
5. La aplicación de PRP en lechos quirúrgicos óseos en modelos experimentales 
animales acelera ligeramente la reparación tisular, pero no mejora la formación 
de hueso a medio plazo. 
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